CN110072865B - 吡咯并芳杂环类化合物及其制备方法和医药用途 - Google Patents
吡咯并芳杂环类化合物及其制备方法和医药用途 Download PDFInfo
- Publication number
- CN110072865B CN110072865B CN201780076186.0A CN201780076186A CN110072865B CN 110072865 B CN110072865 B CN 110072865B CN 201780076186 A CN201780076186 A CN 201780076186A CN 110072865 B CN110072865 B CN 110072865B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- pyrrolo
- pyrimidin
- oxy
- acrylamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 144
- 150000001875 compounds Chemical class 0.000 claims abstract description 171
- 230000000694 effects Effects 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 11
- 230000004054 inflammatory process Effects 0.000 claims abstract description 11
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 229940125814 BTK kinase inhibitor Drugs 0.000 claims abstract description 3
- -1 tetrahydroimidazolyl Chemical group 0.000 claims description 152
- 125000000217 alkyl group Chemical group 0.000 claims description 118
- 125000000623 heterocyclic group Chemical group 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 59
- 229910052736 halogen Inorganic materials 0.000 claims description 49
- 150000002367 halogens Chemical class 0.000 claims description 49
- 239000001257 hydrogen Substances 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 35
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 16
- 206010003246 arthritis Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 150000003254 radicals Chemical class 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 201000000306 sarcoidosis Diseases 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 abstract description 11
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 201
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 172
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- 238000006243 chemical reaction Methods 0.000 description 128
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 125000000753 cycloalkyl group Chemical group 0.000 description 76
- 238000004949 mass spectrometry Methods 0.000 description 69
- 238000005160 1H NMR spectroscopy Methods 0.000 description 67
- 230000015572 biosynthetic process Effects 0.000 description 51
- 239000000047 product Substances 0.000 description 51
- 238000003786 synthesis reaction Methods 0.000 description 51
- 230000002829 reductive effect Effects 0.000 description 48
- 239000000243 solution Substances 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 125000003545 alkoxy group Chemical group 0.000 description 39
- 238000004440 column chromatography Methods 0.000 description 39
- 239000007787 solid Substances 0.000 description 39
- 239000003480 eluent Substances 0.000 description 38
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 35
- 125000001072 heteroaryl group Chemical group 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 125000003118 aryl group Chemical group 0.000 description 32
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 25
- 239000000651 prodrug Substances 0.000 description 25
- 229940002612 prodrug Drugs 0.000 description 25
- LSKYURVDOIDSCG-UHFFFAOYSA-N [4-(4-methylpiperazin-1-yl)phenyl]boronic acid Chemical compound C1CN(C)CCN1C1=CC=C(B(O)O)C=C1 LSKYURVDOIDSCG-UHFFFAOYSA-N 0.000 description 21
- 125000003342 alkenyl group Chemical group 0.000 description 20
- 125000000304 alkynyl group Chemical group 0.000 description 20
- 125000004093 cyano group Chemical group *C#N 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 17
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- 108091000080 Phosphotransferase Proteins 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 102000020233 phosphotransferase Human genes 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- 210000003719 b-lymphocyte Anatomy 0.000 description 15
- 229940018563 3-aminophenol Drugs 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 13
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 235000011114 ammonium hydroxide Nutrition 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 125000003367 polycyclic group Chemical group 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- 125000004043 oxo group Chemical group O=* 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- YDNMNPHZKMEGDR-UHFFFAOYSA-N 4-(4-bromophenyl)-1,4-thiazinane 1,1-dioxide Chemical compound C1=CC(Br)=CC=C1N1CCS(=O)(=O)CC1 YDNMNPHZKMEGDR-UHFFFAOYSA-N 0.000 description 8
- 229910003827 NRaRb Inorganic materials 0.000 description 8
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 description 8
- 125000005366 cycloalkylthio group Chemical group 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000003513 alkali Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- WHDIUBHAKZDSJL-UHFFFAOYSA-N (4-morpholin-4-ylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1N1CCOCC1 WHDIUBHAKZDSJL-UHFFFAOYSA-N 0.000 description 6
- REGBCJJLGBXDCZ-UHFFFAOYSA-N 2-[[4-chloro-6-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl-trimethylsilane Chemical compound ClC=1C2=C(N=CN=1)N(C(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)COCC[Si](C)(C)C REGBCJJLGBXDCZ-UHFFFAOYSA-N 0.000 description 6
- IBNDLDKHLKDDRZ-UHFFFAOYSA-N 2-methyl-2,6-diazaspiro[3.3]heptane;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CC11CNC1 IBNDLDKHLKDDRZ-UHFFFAOYSA-N 0.000 description 6
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 6
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 6
- 229940124291 BTK inhibitor Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- HBBYQVLWDZKQRU-UHFFFAOYSA-N 3-[6-[4-(4-methylpiperazin-1-yl)phenyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]oxyaniline Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(N)C=CC=2)N1COCC[Si](C)(C)C HBBYQVLWDZKQRU-UHFFFAOYSA-N 0.000 description 5
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 5
- IGTOHVLPYJUKFE-UHFFFAOYSA-N 4-(dimethylamino)-N-[3-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]but-2-enamide Chemical compound CN(CC=CC(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)C IGTOHVLPYJUKFE-UHFFFAOYSA-N 0.000 description 5
- VIZMARKIEQIMIG-UHFFFAOYSA-N 4-bromo-5-chloropyridin-2-amine Chemical compound NC1=CC(Br)=C(Cl)C=N1 VIZMARKIEQIMIG-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 239000012445 acidic reagent Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000005936 piperidyl group Chemical group 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 4
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 4
- VJCSFNNTQGRAKH-UHFFFAOYSA-N 3-amino-4-fluorophenol Chemical compound NC1=CC(O)=CC=C1F VJCSFNNTQGRAKH-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- AQSKMMDRZNILBG-UHFFFAOYSA-N N-but-2-ynyl-3-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]aniline Chemical compound CC#CCNC1=CC(=CC=C1)OC2=NC=NC3=C2C=C(N3)C4=CC=C(C=C4)N5CCN(CC5)C AQSKMMDRZNILBG-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000003435 antirheumatic agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- PMHOLXNNEPPFNZ-UHFFFAOYSA-N n-(3-hydroxyphenyl)prop-2-enamide Chemical compound OC1=CC=CC(NC(=O)C=C)=C1 PMHOLXNNEPPFNZ-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 3
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 description 3
- QRVVOGHYNZAOML-UHFFFAOYSA-N 2-[(6-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound BrC1=CC2=C(N=CN=C2Cl)N1COCC[Si](C)(C)C QRVVOGHYNZAOML-UHFFFAOYSA-N 0.000 description 3
- CBUOGMOTDGNEAW-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CBr)C=C1 CBUOGMOTDGNEAW-UHFFFAOYSA-N 0.000 description 3
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- QIOIBAIABQUDNG-UHFFFAOYSA-N N-[3-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C QIOIBAIABQUDNG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940125890 compound Ia Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229940018564 m-phenylenediamine Drugs 0.000 description 3
- 210000001595 mastoid Anatomy 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- IBWRNPLEYCUSLZ-UHFFFAOYSA-N 1-(4-bromophenyl)-4-(2,2,2-trifluoroethyl)piperazine Chemical compound C1CN(CC(F)(F)F)CCN1C1=CC=C(Br)C=C1 IBWRNPLEYCUSLZ-UHFFFAOYSA-N 0.000 description 2
- YDVSFRZKQMQPJD-UHFFFAOYSA-N 1-(4-bromophenyl)piperazine;hydrochloride Chemical compound [Cl-].C1=CC(Br)=CC=C1N1CC[NH2+]CC1 YDVSFRZKQMQPJD-UHFFFAOYSA-N 0.000 description 2
- VSRLIXHYPWDUSU-UHFFFAOYSA-N 1-(4-ethynylphenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(C#C)C=C1 VSRLIXHYPWDUSU-UHFFFAOYSA-N 0.000 description 2
- HJKVRMHVLINDRH-UHFFFAOYSA-N 1-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]piperidine Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1CN1CCCCC1 HJKVRMHVLINDRH-UHFFFAOYSA-N 0.000 description 2
- RDFJBDMCBVSCFI-UHFFFAOYSA-N 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine Chemical compound C1CN(C)CCN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 RDFJBDMCBVSCFI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- RSFJWURSQDDQSJ-UHFFFAOYSA-N 2-(4-iodophenyl)-6-methyl-2,6-diazaspiro[3.3]heptane Chemical compound C1N(C)CC21CN(C=1C=CC(I)=CC=1)C2 RSFJWURSQDDQSJ-UHFFFAOYSA-N 0.000 description 2
- GRWPTSXPZYCYOM-UHFFFAOYSA-N 2-(dimethylamino)acetaldehyde Chemical compound CN(C)CC=O GRWPTSXPZYCYOM-UHFFFAOYSA-N 0.000 description 2
- BXLIYHJSKXWJOW-UHFFFAOYSA-N 2-[[4-chloro-6-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl-trimethylsilane Chemical compound ClC=1C2=C(N=CN=1)N(C(=C2)C1=CC=C(CN2CCS(CC2)(=O)=O)C=C1)COCC[Si](C)(C)C BXLIYHJSKXWJOW-UHFFFAOYSA-N 0.000 description 2
- YSMNZODWXGMHOF-UHFFFAOYSA-N 2-[[4-chloro-6-[4-[(4,4-difluoropiperidin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl-trimethylsilane Chemical compound ClC=1C2=C(N=CN=1)N(C(=C2)C1=CC=C(C=C1)CN1CCC(CC1)(F)F)COCC[Si](C)(C)C YSMNZODWXGMHOF-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- UBKYFFBIDHKFAH-UHFFFAOYSA-N 3-[6-[4-[(4,4-difluoropiperidin-1-yl)methyl]phenyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]oxyaniline Chemical compound FC1(CCN(CC1)CC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(N)C=CC=2)N1COCC[Si](C)(C)C)F UBKYFFBIDHKFAH-UHFFFAOYSA-N 0.000 description 2
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 2
- PFODEVGLOVUVHS-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)benzaldehyde Chemical compound C1CN(C)CCN1C1=CC=C(C=O)C=C1 PFODEVGLOVUVHS-UHFFFAOYSA-N 0.000 description 2
- PGWVUZCQLVXPJL-UHFFFAOYSA-N 4-(dimethylamino)-N-[2-fluoro-5-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]but-2-enamide Chemical compound CN(CC=CC(=O)NC1=C(C=CC(=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)F)C PGWVUZCQLVXPJL-UHFFFAOYSA-N 0.000 description 2
- LBRKNRRGBACAAF-UHFFFAOYSA-N 4-[4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]-1,4-thiazinane 1,1-dioxide Chemical compound ClC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCS(CC1)(=O)=O LBRKNRRGBACAAF-UHFFFAOYSA-N 0.000 description 2
- VESMNSNSBTYZDA-UHFFFAOYSA-N 4-[cyclopropyl(methyl)amino]-N-[3-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]but-2-enamide Chemical compound C1(CC1)N(CC=CC(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)C VESMNSNSBTYZDA-UHFFFAOYSA-N 0.000 description 2
- OEVZDNFJXBTHMC-UHFFFAOYSA-N 4-bromo-5-chloro-2-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridine Chemical compound BrC1=C2C(=NC=C1Cl)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C OEVZDNFJXBTHMC-UHFFFAOYSA-N 0.000 description 2
- ATDCFPJTMNQWBY-UHFFFAOYSA-N 4-bromo-5-chloro-3-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyridin-2-amine Chemical compound BrC1=C(C(=NC=C1Cl)N)C#CC1=CC=C(C=C1)N1CCN(CC1)C ATDCFPJTMNQWBY-UHFFFAOYSA-N 0.000 description 2
- OQPBWSCUHGOSOI-UHFFFAOYSA-N 4-bromo-5-chloro-3-iodopyridin-2-amine Chemical compound NC1=NC=C(Cl)C(Br)=C1I OQPBWSCUHGOSOI-UHFFFAOYSA-N 0.000 description 2
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 2
- AGRYHDADMSHQIT-UHFFFAOYSA-N 4-methyl-1-[4-[4-[3-(prop-2-enoylamino)phenoxy]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]piperazine-2-carboxylic acid Chemical compound C1(=C2C=CC(N3CCN(C)CC3C(=O)O)=C[CH]2)N[C]2C(C(=NC=N2)OC2=CC(NC(=O)C=C)=CC=C2)=C1 AGRYHDADMSHQIT-UHFFFAOYSA-N 0.000 description 2
- YQURLNGUWNDBIR-UHFFFAOYSA-N 5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole Chemical compound C1NCC2CN(C)CC21 YQURLNGUWNDBIR-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ZLTBRKNAHAYVQR-UHFFFAOYSA-N N-[3-[5-chloro-2-[4-(4-methylpiperazin-1-yl)phenyl]-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]oxyphenyl]prop-2-enamide Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(OC3=CC=CC(NC(=O)C=C)=C3)C(Cl)=CN=C2N1COCC[Si](C)(C)C ZLTBRKNAHAYVQR-UHFFFAOYSA-N 0.000 description 2
- ASBUOAZTHWVNAQ-UHFFFAOYSA-N N-[3-[6-[4-(4-methylpiperazin-1-yl)phenyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(OC3=CC=CC(NC(=O)C=C)=C3)N=CN=C2N1COCC[Si](C)(C)C ASBUOAZTHWVNAQ-UHFFFAOYSA-N 0.000 description 2
- XWHNXUBSZREYRE-UHFFFAOYSA-N N-[3-[6-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C[Si](C)(C)CCOCN1C(=CC2=C(OC3=CC=CC(NC(=O)C=C)=C3)N=CN=C12)C1=CC=C(CN2CCS(=O)(=O)CC2)C=C1 XWHNXUBSZREYRE-UHFFFAOYSA-N 0.000 description 2
- FHKPGYHERSXBIF-UHFFFAOYSA-N N-[3-[[5-chloro-2-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound ClC=1C(=C2C(=NC=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)OC=1C=C(C=CC=1)NC(C=C)=O FHKPGYHERSXBIF-UHFFFAOYSA-N 0.000 description 2
- VQPZAIUQFJRMEN-UHFFFAOYSA-N N-[3-[[6-[4-(1,1-dioxo-1,4-thiazinan-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCS(CC1)(=O)=O VQPZAIUQFJRMEN-UHFFFAOYSA-N 0.000 description 2
- IXAIEGKUZZIOPU-UHFFFAOYSA-N N-[3-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C IXAIEGKUZZIOPU-UHFFFAOYSA-N 0.000 description 2
- YBZYVAZZZQKBQE-UHFFFAOYSA-N N-[3-[[6-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound O=S1(CCN(CC1)CC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1)=O YBZYVAZZZQKBQE-UHFFFAOYSA-N 0.000 description 2
- 102000004422 Phospholipase C gamma Human genes 0.000 description 2
- 108010056751 Phospholipase C gamma Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 2
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 2
- RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- LUEHNHVFDCZTGL-UHFFFAOYSA-N but-2-ynoic acid Chemical compound CC#CC(O)=O LUEHNHVFDCZTGL-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000001145 finger joint Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- DEKGLRDTPBZZBL-UHFFFAOYSA-N n-(4-bromophenyl)-1-methylpiperidin-4-amine Chemical compound C1CN(C)CCC1NC1=CC=C(Br)C=C1 DEKGLRDTPBZZBL-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- VEBLEROFGPOMPB-UHFFFAOYSA-N n-methylcyclopropanamine Chemical compound CNC1CC1 VEBLEROFGPOMPB-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical group CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FTAGZJAFWFNHAP-UHFFFAOYSA-N (4-bromophenyl)-morpholin-4-ylmethanone Chemical compound C1=CC(Br)=CC=C1C(=O)N1CCOCC1 FTAGZJAFWFNHAP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- LFMWZTSOMGDDJU-UHFFFAOYSA-N 1,4-diiodobenzene Chemical compound IC1=CC=C(I)C=C1 LFMWZTSOMGDDJU-UHFFFAOYSA-N 0.000 description 1
- DPGNULCSJLDVBD-UHFFFAOYSA-N 1-(4-bromophenyl)-4-ethylsulfonylpiperazine Chemical compound C1CN(S(=O)(=O)CC)CCN1C1=CC=C(Br)C=C1 DPGNULCSJLDVBD-UHFFFAOYSA-N 0.000 description 1
- CBNDEXDYZUNXBF-UHFFFAOYSA-N 1-(4-bromophenyl)sulfonyl-4-methylpiperazine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(Br)C=C1 CBNDEXDYZUNXBF-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- RFECQDXNBWGCRR-UHFFFAOYSA-N 1-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1F RFECQDXNBWGCRR-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VLYJJEFDTKMUIC-UHFFFAOYSA-N 1-methyl-N-[4-[4-[3-(prop-2-enoylamino)phenoxy]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]piperidine-4-carboxamide Chemical compound C1(=C2C=CC(=C[CH]2)NC(=O)C2CCN(CC2)C)N[C]2C(=C1)C(=NC=N2)OC1=CC(NC(=O)C=C)=CC=C1 VLYJJEFDTKMUIC-UHFFFAOYSA-N 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- UMWAQXIWHSVZDX-UHFFFAOYSA-N 2-[[4-bromo-5-chloro-2-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[2,3-b]pyridin-1-yl]methoxy]ethyl-trimethylsilane Chemical compound BrC1=C2C(=NC=C1Cl)N(C(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)COCC[Si](C)(C)C UMWAQXIWHSVZDX-UHFFFAOYSA-N 0.000 description 1
- HQNIMNQVKVPZES-UHFFFAOYSA-N 2-amino-1h-pyridin-4-one Chemical compound NC1=CC(O)=CC=N1 HQNIMNQVKVPZES-UHFFFAOYSA-N 0.000 description 1
- AUTIKIFHJHJLED-UHFFFAOYSA-N 2-amino-4-hydroxybenzonitrile Chemical compound NC1=CC(O)=CC=C1C#N AUTIKIFHJHJLED-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- IHQUZBAICQKAMU-UHFFFAOYSA-N 2-diethoxyphosphoryl-N-[3-[6-[4-(4-methylpiperazin-1-yl)phenyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]acetamide Chemical compound CCOP(=O)(CC(=O)NC1=CC(OC2=C3C=C(N(COCC[Si](C)(C)C)C3=NC=N2)C2=CC=C(C=C2)N2CCN(C)CC2)=CC=C1)OCC IHQUZBAICQKAMU-UHFFFAOYSA-N 0.000 description 1
- ZZPNDIHOQDQVNU-UHFFFAOYSA-N 2-hydroxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical class CC1(C)OB(O)OC1(C)C ZZPNDIHOQDQVNU-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- JPWAEVGDXGPTHE-UHFFFAOYSA-N 3-N-[6-[4-(4-methylpiperazin-1-yl)phenyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]benzene-1,3-diamine Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(N=CN=C2NC2=CC(=CC=C2)N)N1COCC[Si](C)(C)C JPWAEVGDXGPTHE-UHFFFAOYSA-N 0.000 description 1
- ZJSPGKIXIYMITF-UHFFFAOYSA-N 3-[5-chloro-2-[4-(4-methylpiperazin-1-yl)phenyl]-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]oxyaniline Chemical compound ClC=1C(=C2C(=NC=1)N(C(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)COCC[Si](C)(C)C)OC=1C=C(C=CC=1)N ZJSPGKIXIYMITF-UHFFFAOYSA-N 0.000 description 1
- HEAHXMOKYXTEID-UHFFFAOYSA-N 3-amino-4-methoxyphenol Chemical compound COC1=CC=C(O)C=C1N HEAHXMOKYXTEID-UHFFFAOYSA-N 0.000 description 1
- NUNAWQZKZVVELQ-UHFFFAOYSA-N 3-amino-4-methylphenol Chemical compound CC1=CC=C(O)C=C1N NUNAWQZKZVVELQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- CFPCKNVBSYLJHT-UHFFFAOYSA-N 3-methyl-3,8-diazabicyclo[3.2.1]octane;dihydrochloride Chemical compound Cl.Cl.C1N(C)CC2CCC1N2 CFPCKNVBSYLJHT-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- DYNWNNKAUGBOOZ-UHFFFAOYSA-N 3-n-methylbenzene-1,3-diamine Chemical compound CNC1=CC=CC(N)=C1 DYNWNNKAUGBOOZ-UHFFFAOYSA-N 0.000 description 1
- XVFDTMOEUDZZFE-UHFFFAOYSA-N 4-(4-bromophenyl)-1-methylpiperidine Chemical compound C1CN(C)CCC1C1=CC=C(Br)C=C1 XVFDTMOEUDZZFE-UHFFFAOYSA-N 0.000 description 1
- QDSFNOHWQKVVEB-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)morpholine Chemical compound CCOP(=O)(OCC)CN1CCOCC1 QDSFNOHWQKVVEB-UHFFFAOYSA-N 0.000 description 1
- RTZGDDKHGKZLCO-UHFFFAOYSA-N 4-bromo-5-fluoropyridin-2-amine Chemical compound NC1=CC(Br)=C(F)C=N1 RTZGDDKHGKZLCO-UHFFFAOYSA-N 0.000 description 1
- GFIZLNBSILWOTG-UHFFFAOYSA-N 4-bromo-5-methylpyridin-2-amine Chemical compound CC1=CN=C(N)C=C1Br GFIZLNBSILWOTG-UHFFFAOYSA-N 0.000 description 1
- AYVPVDWQZAAZCM-UHFFFAOYSA-N 4-bromo-n-methylaniline Chemical compound CNC1=CC=C(Br)C=C1 AYVPVDWQZAAZCM-UHFFFAOYSA-N 0.000 description 1
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- LJMBMKKMKAFQAV-UHFFFAOYSA-N 4-methylpiperazin-1-ium-2-carboxylate Chemical compound CN1CCNC(C(O)=O)C1 LJMBMKKMKAFQAV-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XOHGAUWNZXRBFP-UHFFFAOYSA-N 6-amino-4-bromopyridine-3-carbonitrile Chemical compound Nc1cc(Br)c(cn1)C#N XOHGAUWNZXRBFP-UHFFFAOYSA-N 0.000 description 1
- NJPXMLQSSKQIJH-UHFFFAOYSA-N 6-bromo-4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=C(Br)N2 NJPXMLQSSKQIJH-UHFFFAOYSA-N 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 101150030812 BTK gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- KBVYWAORTOTQJD-UHFFFAOYSA-N N-[2-cyano-5-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(#N)C1=C(C=C(C=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)NC(C=C)=O KBVYWAORTOTQJD-UHFFFAOYSA-N 0.000 description 1
- JHRUIPVORYIKNY-UHFFFAOYSA-N N-[2-fluoro-5-[[6-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound FC1=C(C=C(C=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCOCC1)NC(C=C)=O JHRUIPVORYIKNY-UHFFFAOYSA-N 0.000 description 1
- LXMVMQVHCVTDKJ-UHFFFAOYSA-N N-[2-fluoro-5-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(N3CCN(C)CC3)=C[CH]2)N[C]2C(C(=NC=N2)OC2=CC(NC(=O)C=C)=C(F)C=C2)=C1 LXMVMQVHCVTDKJ-UHFFFAOYSA-N 0.000 description 1
- BTIPADKFSQOSEW-UHFFFAOYSA-N N-[2-methoxy-5-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound COC1=C(C=C(C=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)NC(C=C)=O BTIPADKFSQOSEW-UHFFFAOYSA-N 0.000 description 1
- NXGAIJHZDUCISH-UHFFFAOYSA-N N-[2-methyl-5-[[6-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CC1=C(C=C(C=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCOCC1)NC(C=C)=O NXGAIJHZDUCISH-UHFFFAOYSA-N 0.000 description 1
- HDYGMFKWBUWFBW-UHFFFAOYSA-N N-[3-[[5-cyano-2-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC1=C2C(=NC=C1C#N)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C HDYGMFKWBUWFBW-UHFFFAOYSA-N 0.000 description 1
- ZGOZWTMTXTWHNJ-UHFFFAOYSA-N N-[3-[[5-fluoro-2-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound FC=1C(=C2C(=NC=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C)OC=1C=C(C=CC=1)NC(C=C)=O ZGOZWTMTXTWHNJ-UHFFFAOYSA-N 0.000 description 1
- LIYMGDQXMSCGEY-UHFFFAOYSA-N N-[3-[[5-methyl-2-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC1=C2C(=NC=C1C)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C LIYMGDQXMSCGEY-UHFFFAOYSA-N 0.000 description 1
- UYDHIHQEGRNONJ-UHFFFAOYSA-N N-[3-[[6-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C=CC(=O)Nc1cccc(Nc2ncnc3[nH]c(cc23)-c2ccc(cc2)N2CCOCC2)c1 UYDHIHQEGRNONJ-UHFFFAOYSA-N 0.000 description 1
- KLSYFSMLPFKXDQ-UHFFFAOYSA-N N-[3-[[6-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C=CC(=O)Nc1cccc(Oc2ncnc3[nH]c(cc23)-c2ccc(cc2)N2CCOCC2)c1 KLSYFSMLPFKXDQ-UHFFFAOYSA-N 0.000 description 1
- UMPWLWBUUUHFIM-UHFFFAOYSA-N N-[3-[[6-(4-piperazin-1-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N1(CCNCC1)C1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 UMPWLWBUUUHFIM-UHFFFAOYSA-N 0.000 description 1
- ZJXHAMDTCLMCJL-UHFFFAOYSA-N N-[3-[[6-[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(F)=C(C=2NC3=NC=NC(=C3C=2)OC2=CC(NC(=O)C=C)=CC=C2)C=CC(N2CCN(C)CC2)=C1 ZJXHAMDTCLMCJL-UHFFFAOYSA-N 0.000 description 1
- JLDDWYCXYFXHGH-UHFFFAOYSA-N N-[3-[[6-[3-(difluoromethoxy)-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound FC(OC=1C=C(C=CC=1N1CCN(CC1)C)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1)F JLDDWYCXYFXHGH-UHFFFAOYSA-N 0.000 description 1
- ZWAFYNIMIFJHBD-UHFFFAOYSA-N N-[3-[[6-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound FC=1C=C(C=CC=1N1CCN(CC1)C)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 ZWAFYNIMIFJHBD-UHFFFAOYSA-N 0.000 description 1
- HRHMRLLYZZSCBE-UHFFFAOYSA-N N-[3-[[6-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound COC=1C=C(C=CC=1N1CCN(CC1)C)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 HRHMRLLYZZSCBE-UHFFFAOYSA-N 0.000 description 1
- JOXGSXJZOBODJU-UHFFFAOYSA-N N-[3-[[6-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CC=1C=C(C=CC=1N1CCN(CC1)C)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 JOXGSXJZOBODJU-UHFFFAOYSA-N 0.000 description 1
- GDPPWWUMZXUAMR-UHFFFAOYSA-N N-[3-[[6-[4-(1-methylpiperidin-4-yl)oxyphenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)OC1CCN(CC1)C GDPPWWUMZXUAMR-UHFFFAOYSA-N 0.000 description 1
- SGEBGBVRUAHJCY-UHFFFAOYSA-N N-[3-[[6-[4-(2,4-dimethylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1C(CN(CC1)C)C SGEBGBVRUAHJCY-UHFFFAOYSA-N 0.000 description 1
- IBCZOOAITOBCSY-UHFFFAOYSA-N N-[3-[[6-[4-(2-methoxyethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound COCCOC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 IBCZOOAITOBCSY-UHFFFAOYSA-N 0.000 description 1
- FXPIZHJBLQEBCF-UHFFFAOYSA-N N-[3-[[6-[4-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN1CC2C(C1)CN(C2)C1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 FXPIZHJBLQEBCF-UHFFFAOYSA-N 0.000 description 1
- ZBIBRBBEYRTGEW-UHFFFAOYSA-N N-[3-[[6-[4-(4,4-difluoropiperidin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(N3CCC(CC3)(F)F)=C[CH]2)NC2=NC=N[C](C2=C1)OC1=CC(NC(=O)C=C)=CC=C1 ZBIBRBBEYRTGEW-UHFFFAOYSA-N 0.000 description 1
- MZSRGLSOMJAQNU-UHFFFAOYSA-N N-[3-[[6-[4-(4-acetylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C(C)=O MZSRGLSOMJAQNU-UHFFFAOYSA-N 0.000 description 1
- MNDVNQZHEREAKZ-UHFFFAOYSA-N N-[3-[[6-[4-(4-ethylsulfonylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C)S(=O)(=O)N1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 MNDVNQZHEREAKZ-UHFFFAOYSA-N 0.000 description 1
- KEPIAOHNCSPYPK-UHFFFAOYSA-N N-[3-[[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]sulfanyl]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)SC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)N1CCN(CC1)C KEPIAOHNCSPYPK-UHFFFAOYSA-N 0.000 description 1
- XGTKRUYGAJZDNL-UHFFFAOYSA-N N-[3-[[6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(=C[CH]2)S(=O)(=O)N2CCN(CC2)C)N[C]2C(=C1)C(=NC=N2)OC1=CC(NC(=O)C=C)=CC=C1 XGTKRUYGAJZDNL-UHFFFAOYSA-N 0.000 description 1
- YNVOXLMSOVFVNH-UHFFFAOYSA-N N-[3-[[6-[4-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN1CC2(CN(C2)C2=CC=C(C=C2)C2=CC3=C(N=CN=C3OC=3C=C(C=CC=3)NC(C=C)=O)N2)C1 YNVOXLMSOVFVNH-UHFFFAOYSA-N 0.000 description 1
- IOBNZQSJTBXOEK-UHFFFAOYSA-N N-[3-[[6-[4-(dimethylamino)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN(C1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1)C IOBNZQSJTBXOEK-UHFFFAOYSA-N 0.000 description 1
- URHDFHVRZNYYNP-UHFFFAOYSA-N N-[3-[[6-[4-(morpholin-4-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C=CC(=O)Nc1cccc(Oc2ncnc3[nH]c(cc23)-c2ccc(CN3CCOCC3)cc2)c1 URHDFHVRZNYYNP-UHFFFAOYSA-N 0.000 description 1
- XTOMDNWWIIEYQV-UHFFFAOYSA-N N-[3-[[6-[4-(piperidin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N1(CCCCC1)CC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 XTOMDNWWIIEYQV-UHFFFAOYSA-N 0.000 description 1
- CJPYIXWPBDXVFX-UHFFFAOYSA-N N-[3-[[6-[4-(pyrrolidin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N1(CCCC1)CC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 CJPYIXWPBDXVFX-UHFFFAOYSA-N 0.000 description 1
- FTZASNAMIXVFEC-UHFFFAOYSA-N N-[3-[[6-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(CN3CCS(=O)(=O)CC3)=C[CH]2)NC2=NC=N[C](C2=C1)NC1=CC(NC(=O)C=C)=CC=C1 FTZASNAMIXVFEC-UHFFFAOYSA-N 0.000 description 1
- QTNBCTFMDIJPMQ-UHFFFAOYSA-N N-[3-[[6-[4-[(1-methylpiperidin-4-yl)amino]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C1=CC=C(C=C1)NC1CCN(CC1)C QTNBCTFMDIJPMQ-UHFFFAOYSA-N 0.000 description 1
- ZYDOQTMVNDIXAV-UHFFFAOYSA-N N-[3-[[6-[4-[(1-methylpiperidin-4-yl)oxymethyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(COC3CCN(CC3)C)=C[CH]2)N[C]2C(C(=NC=N2)OC2=CC(NC(=O)C=C)=CC=C2)=C1 ZYDOQTMVNDIXAV-UHFFFAOYSA-N 0.000 description 1
- FBDLTCGAFBQPOJ-UHFFFAOYSA-N N-[3-[[6-[4-[(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN1CC2C(C1)CN(C2)CC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 FBDLTCGAFBQPOJ-UHFFFAOYSA-N 0.000 description 1
- IUOZVPDUTBSBLY-UHFFFAOYSA-N N-[3-[[6-[4-[(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(CN3C4CN(CC3CC4)C)=C[CH]2)NC2=NC=N[C](C2=C1)OC1=CC(NC(=O)C=C)=CC=C1 IUOZVPDUTBSBLY-UHFFFAOYSA-N 0.000 description 1
- TYGWSKXIHGVQOB-UHFFFAOYSA-N N-[3-[[6-[4-[(4,4-difluoropiperidin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(CN3CCC(F)(F)CC3)=C[CH]2)N[C]2C(C(=NC=N2)OC2=CC(NC(=O)C=C)=CC=C2)=C1 TYGWSKXIHGVQOB-UHFFFAOYSA-N 0.000 description 1
- VPMRGAIBVUHDLW-UHFFFAOYSA-N N-[3-[[6-[4-[(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN1CC2(CN(C2)CC2=CC=C(C=C2)C2=CC3=C(N=CN=C3OC=3C=C(C=CC=3)NC(C=C)=O)N2)C1 VPMRGAIBVUHDLW-UHFFFAOYSA-N 0.000 description 1
- PIJMTKCMJFXJKM-UHFFFAOYSA-N N-[3-[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN(C)CC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 PIJMTKCMJFXJKM-UHFFFAOYSA-N 0.000 description 1
- ULQSADYHOOTOHB-UHFFFAOYSA-N N-[3-[[6-[4-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound FC(CN1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1)(F)F ULQSADYHOOTOHB-UHFFFAOYSA-N 0.000 description 1
- QKESOMFMWUWGAM-UHFFFAOYSA-N N-[3-[[6-[4-[[(1-methylpiperidin-4-yl)amino]methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(CNC3CCN(CC3)C)=C[CH]2)N[C]2C(=C1)C(=NC=N2)OC1=CC(NC(=O)C=C)=CC=C1 QKESOMFMWUWGAM-UHFFFAOYSA-N 0.000 description 1
- RDXQRRSHTOGAOM-UHFFFAOYSA-N N-[3-[[6-[4-[[methyl-(1-methylpiperidin-4-yl)amino]methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN(C1CCN(CC1)C)CC1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1 RDXQRRSHTOGAOM-UHFFFAOYSA-N 0.000 description 1
- QQDCGWBLPZXKNI-UHFFFAOYSA-N N-[3-[[6-[4-[methyl-(1-methylpiperidin-4-yl)amino]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound CN(C1=CC=C(C=C1)C1=CC2=C(N=CN=C2OC=2C=C(C=CC=2)NC(C=C)=O)N1)C1CCN(CC1)C QQDCGWBLPZXKNI-UHFFFAOYSA-N 0.000 description 1
- YAXFOBCVLVREFX-UHFFFAOYSA-N N-[3-[[6-[5-(4-methylpiperazin-1-yl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C=1(N=CC(=CC=1)N1CCN(CC1)C)C=1NC2=C(C=1)C(=NC=N2)OC1=CC(NC(=O)C=C)=CC=C1 YAXFOBCVLVREFX-UHFFFAOYSA-N 0.000 description 1
- OQPQHCUYQVVYQI-UHFFFAOYSA-N N-[3-[[6-[5-[(4,4-difluoropiperidin-1-yl)methyl]pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1(=CC=C(N=C1)C=1NC2=C(C(=NC=N2)OC2=CC(NC(=O)C=C)=CC=C2)C=1)CN1CCC(CC1)(F)F OQPQHCUYQVVYQI-UHFFFAOYSA-N 0.000 description 1
- DZZLSYFUYNLSCB-UHFFFAOYSA-N N-[3-[[6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=CN=1)NC(=C2)C=1C=NC(=CC=1)N1CCN(CC1)C DZZLSYFUYNLSCB-UHFFFAOYSA-N 0.000 description 1
- NRJMLBAQYDRFOT-UHFFFAOYSA-N N-[3-[methyl-[6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C1(=C2C=CC(N3CCN(C)CC3)=C[CH]2)N[C]2C(C(=NC=N2)N(C2=CC(NC(=O)C=C)=CC=C2)C)=C1 NRJMLBAQYDRFOT-UHFFFAOYSA-N 0.000 description 1
- IMUXIVXQAQFNEA-UHFFFAOYSA-N N-[4-[[6-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]pyridin-2-yl]prop-2-enamide Chemical compound C1(=C2C=CC(N3CCOCC3)=C[CH]2)NC2=NC=N[C](C2=C1)OC1=CC(NC(=O)C=C)=NC=C1 IMUXIVXQAQFNEA-UHFFFAOYSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- CLCPKAQBNOIUQN-UHFFFAOYSA-N [4-(2,4-dimethylpiperazin-1-yl)phenyl]boronic acid Chemical compound CC1N(CCN(C1)C)C1=CC=C(C=C1)B(O)O CLCPKAQBNOIUQN-UHFFFAOYSA-N 0.000 description 1
- ODKMFCPXFMQWHA-UHFFFAOYSA-N [4-(2-methoxyethoxy)phenyl]boronic acid Chemical compound COCCOC1=CC=C(B(O)O)C=C1 ODKMFCPXFMQWHA-UHFFFAOYSA-N 0.000 description 1
- RIIPFHVHLXPMHQ-UHFFFAOYSA-N [4-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=C(B(O)O)C=C1 RIIPFHVHLXPMHQ-UHFFFAOYSA-N 0.000 description 1
- LRWRYAVXFZBFRJ-UHFFFAOYSA-N [4-[(dimethylamino)methyl]phenyl]boronic acid Chemical compound CN(C)CC1=CC=C(B(O)O)C=C1 LRWRYAVXFZBFRJ-UHFFFAOYSA-N 0.000 description 1
- UTURWLRUGSGTFY-UHFFFAOYSA-N [5-(4-methylpiperazin-1-yl)pyridin-2-yl]boronic acid Chemical compound CN1CCN(CC1)C=1C=CC(=NC=1)B(O)O UTURWLRUGSGTFY-UHFFFAOYSA-N 0.000 description 1
- YGZOCDXCJWHNQN-UHFFFAOYSA-N [6-(4-methylpiperazin-1-yl)pyridin-3-yl]boronic acid Chemical compound C1CN(C)CCN1C1=CC=C(B(O)O)C=N1 YGZOCDXCJWHNQN-UHFFFAOYSA-N 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- AVTASQJTDUCKMG-UHFFFAOYSA-L disodium;sulfate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O AVTASQJTDUCKMG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- NQYKOGPMIBDYAS-UHFFFAOYSA-N heptane;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCC NQYKOGPMIBDYAS-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XRYGCVVVDCEPRL-UHFFFAOYSA-N n,1-dimethylpiperidin-4-amine Chemical compound CNC1CCN(C)CC1 XRYGCVVVDCEPRL-UHFFFAOYSA-N 0.000 description 1
- MPGBNJKPYBAROJ-UHFFFAOYSA-N n-(4-bromophenyl)-1-methylpiperidine-4-carboxamide Chemical compound C1CN(C)CCC1C(=O)NC1=CC=C(Br)C=C1 MPGBNJKPYBAROJ-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- QKIPWYSRBGTXRG-UHFFFAOYSA-N tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Br)C=C1 QKIPWYSRBGTXRG-UHFFFAOYSA-N 0.000 description 1
- ZMAVVXGWEHZLDW-UHFFFAOYSA-N tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 ZMAVVXGWEHZLDW-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
本发明涉及吡咯并芳杂环类化合物及其制备方法和医药用途。特别地,本发明涉及通式I所示的化合物、其制备方法及含有该化合物的药物组合物,及其作为BTK激酶抑制剂的用途,该化合物及其含有该化合物的药物组合物可以用于治疗与BTK激酶活性相关的疾病,例如炎症、自身免疫性病症、癌症等。其中通式I中的各取代基的定义与说明书中的定义相同。
Description
技术领域
本发明属于医药技术领域,具体涉及一种新的吡咯并芳杂环类化合物、其制备方法及含有其的药物组合物,以及其用于调节Bruton激酶(BTK)活性并且用于治疗和/或预防与BTK活性相关的疾病的用途。
背景技术
胞内信号传递过程是细胞对外界刺激产生反应,并最终引发特异性生物学效应的有效方式。细胞因子能够通过多种信号转导通路进行胞内信号传递,从而参与调控细胞增殖、造血功能和免疫相关的许多重要的生物学功能。蛋白酪氨酸激酶中的Bruton激酶(BTK)在细胞因子信号转导过程中扮演重要角色。
BTK家族是一类非受体酪氨酸蛋白激酶。1952年,Bruton发现X连锁无丙种球蛋白血症(X-linked agammaglobulinemia,XLA)患者体内缺少成熟B细胞,无法有效产生自主免疫应答,基因研究发现该病患者X染色体异常使BTK基因突变,这说明BTK在B细胞的发育成熟中具有重要的作用。BTK不只受到B细胞抗原受体(B cell antigen receptor,BCR)通路的调节参与免疫反应,也受到Toll样受体(Toll like receptor,TLR)信号通路调节参与炎性反应。
BTK家族成员在人体中主要分布于造血组织中,对造血细胞的生长、分化有重要调节作用。其中BTK激酶主要分布于骨髓来源的细胞和B细胞中。BTK包含5个结构域:PH结构域,负责介导蛋白向细胞膜上的转位;TH区域,包含PRR和Btk两个模块;SH2和SH3,对介导BTK与其他蛋白分子间的相互作用有重要作用;以及激酶催化区SH1。
BTK与PI3(磷脂酰肌醇-3-激酶K)、G-蛋白双受体等结合后发生激活,通过PLCγ2(磷脂酶C-γ2)、PKCβI(丝苏氨酸激酶βI)等下游信号分子,参与对血管生成、细胞增殖和凋亡以及细胞运动的调节。在BTK活化的过程中,PH区与磷脂酰肌醇-3,4,5-三磷酸肌醇(PIP3)结合,完成膜转位。膜定位之后的BTK活化并参与两个酪氨酸残基Tyr551和Tyr223的磷酸基团转移,活化环上的Tyr551残基被Src家族酪氨酸激酶磷酸化,导致SH3区的Tyr233自磷酸化,为激酶的完全活化提供必要条件。BTK活化收到PKCβ的负反馈调节,PKCβ磷酸化BTK的Ser180,减少BTK向细胞膜的募集和磷酸基团转移,从而降低其活性。PKC抑制性信号对维持B细胞受体信号通路中BTK活性的平衡具有关键作用。
BTK在B细胞恶性肿瘤发生发展过程中通过BCR和TCR通路发挥重要作用。在多种B细胞恶性肿瘤中以BTK功能为靶点表现出良好的治疗效果:多个BTK抑制剂在针对慢性淋巴细胞白血病、套细胞淋巴瘤、弥漫大B细胞淋巴瘤和多发性骨髓瘤的临床实验中表现出确切疗效。不仅如此,在其他B细胞恶性肿瘤中BTK抑制剂的作用也引起了人们的兴趣,例如发现了MYD88突变和NF-κB信号通路参与的脾脏边缘区淋巴瘤,以及在细胞存活中涉及BCR抗原(和自抗原)识别的滤泡性淋巴瘤。值得注意的是,有系统性自身免疫疾病的病人中弥漫大B细胞淋巴瘤和边缘区淋巴瘤的发病率更高,而BTK通路的激活是自身免疫疾病的重要病理事件,并且临床前实验中BTK抑制剂表现出较强的作用。亦有研究表明BTK具有保护乳腺癌细胞避免凋亡的作用。
风湿性关节炎(RA)是自身免疫疾病,其特征在于关节结构的炎症和破坏。当疾病未受有效治疗,由于关节功能性的丧失导致实质性的失能和疼痛,甚至过早死亡。因此RA治疗的目的不仅延缓疾病进展,而且症状获得减轻,从而终止关节破坏。RA的全球患病率约为0.8%,女性患病几率是男性的三倍。RA难以治疗,目前尚无法治愈,并且治疗集中于缓解疼痛和防止患病关节变性。临床的治疗策略包括非甾体抗炎药物(NSAIDs)、激素、改善病情抗风湿药物(DMARDS)和生物药,主要对关节损坏及肿胀症状进行缓解治疗。临床应用DMARDS(例如甲氨蝶呤、羟化氯喹、来氟米特、柳氮磺胺吡啶)、DMARDS联合生物药的效果比较好。尽管抗RA药物很多,但是30%以上患者的疼痛仍然存在。最新研究表明BTK信号转导通路的干预成为RA治疗一种新方法。
由于T细胞在滑膜腔中大量存在并且在RA中可以激活B细胞,在RA治疗中一直是引人注目的靶点。尽管T细胞共刺激的阻断治疗已经获得许可,但是RA治疗中消耗T细胞表现出的治疗价值十分有限。此外已经证实有疾病进展中B细胞功能和自体抗原的产生。因此人们直接或间接以B细胞为靶点来进行治疗。重要的是,以减少B细胞为目的的疗法有效改善了RA的临床症状,表明B细胞在RA疾病中具有重要作用。以B细胞为靶点(减少B细胞数量或抑制B细胞存活)的疗法在RA中的有效性,证明了B细胞对RA的重要作用。BTK通过参与BCR信号通路对B细胞的成熟和活化具有重要作用。BTK高表达的B细胞中BCR通路加强并引起自身抗体的过表达,从而引发自体免疫反应。因此,BTK是治疗自身免疫性疾病治疗的理想靶点,所述自身免疫性疾病包括但不限于类风湿性关节炎、多发性硬化症、狼疮、银屑病、银屑病性关节炎、炎症性肠炎、克罗恩病、葡萄膜炎、结节病。多个BTK抑制剂在临床前动物模型中显示出很好的治疗自身免疫疾病的疗效。
近年来,BTK抑制剂研发进展较快。已上市药物Ibrutinib主要用于B细胞淋巴瘤的治疗,处于临床中后期的CC-292和ACP-196除用于B细胞淋巴瘤治疗外,还在开发RA等自身免疫疾病适应症。但这些BTK抑制剂普遍具有活性和选择性较低,以及副作用较大等缺点。因此,持续地需要抑制激酶例如Bruton激酶的新型或改进的药剂,以用于开发新的、更有效的药物来治疗RA或其它与BTK相关的疾病。
发明内容
本发明人经过潜心研究,设计合成了一系列含有吡咯并芳杂环骨架的化合物,并对其进行了BTK激酶活性的筛选,研究结果显示该类化合物具有突出的抗BTK激酶的活性,并且可以被开发为治疗与BTK激酶活性相关的疾病的药物。
因此,本发明的目的在于提供一种通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中:
W选自N或CR1;
R1选自氢、卤素、氰基、烷基;
X选自-O-、-NR2-、-CH2-、-S-、-SO-、-SO2-、-CO-;
R2选自氢、烷基、环烷基;其中所述烷基、环烷基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基、酯基、烷基、烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
Y选自芳基、杂芳基;其中所述芳基、杂芳基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基、酯基、烷基、烷氧基、卤代烷基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
n是0至4的整数;
R3选自氢、烷基、环烷基;其中所述烷基、环烷基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基、酯基、烷基、烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
R4和R5各自独立地选自氢、烷基,其中所述烷基任选进一步被选自杂环基、-NRaRb的一个或多个基团取代,所述杂环基任选进一步被卤素或烷基取代;
Cy选自芳基、杂芳基,其中所述芳基、杂芳基任选进一步被选自卤素、氨基、硝基、氰基、羟基、巯基、羧基、酯基、氧代基、烷基、烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基、卤代烷基、卤代烷氧基的一个或多个基团取代;
L1和L2各自独立地选自单键、-(CH2)m-、-O-、-NR6-、-S-、-SO-、-SO2-和-CO-中的一种或多种;
m是1至4的整数;
R6选自氢、烷基、环烷基;其中所述烷基、环烷基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基、酯基、烷基、烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
R7选自烷基、环烷基、杂环基;其中所述烷基、环烷基、杂环基任选进一步被一个或多个R8取代;
每个R8各自独立地选自卤素、氨基、硝基、氰基、羟基、巯基、氧代基、烷基、烷氧基、环烷基、杂环基、芳基、杂芳基、-C(O)Ra、-O(O)C Ra、-C(O)ORa、-C(O)NRaRb、-NHC(O)Ra、-S(O)Ra、-S(O)2Ra、-S(O)NRaRb、-NRaRb、-S(O)2NRaRb、-NHS(O)Ra、-NHS(O)2Ra;其中所述烷基、烷氧基、环烷基、杂环基、芳基、杂芳基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基、酯基、烷基、烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
Ra和Rb各自独立地选自氢、卤素、羟基、烷基、烯基、炔基、环烷基、杂环基、芳基、杂芳基,其中所述烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基任选进一步被选自卤素、氨基、硝基、氰基、羟基、巯基、羧基、酯基、氧代基、烷基、烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
或者Ra和Rb与他们连接的氮原子一起形成含氮杂环基,所述含氮杂环基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基、酯基、烷基、烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代。
在本发明一个优选的实施方案中,根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其中,
X选自-O-,-S-和-NR2-,
R2选自氢、烷基、和环烷基,所述烷基优选C1-C12烷基,更优选C1-C6烷基,所述环烷基优选C3-C12环烷基,更优选C3-C6环烷基。
在本发明另一个优选的实施方案中,根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其中,
Y选自C6-C10芳基或5至10元杂芳基,优选苯基或吡啶基,所述芳基或杂芳基任选进一步被选自卤素、氰基、烷基、烷氧基、卤代烷基、卤代烷氧基的一个或多个基团取代,所述烷基优选C1-C12烷基,更优选C1-C6烷基,所述烷氧基优选C1-C12烷氧基,更优选C1-C6烷氧基。
在本发明另一个优选的实施方案中,根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其中,
n是0;
R3选自氢、烷基、环烷基;
R4和R5各自独立地选自氢、烷基,其中所述烷基任选进一步被选自-NRaRb的一个或多个基团取代;
Ra和Rb各自独立地选自氢、烷基、环烷基;
或者Ra和Rb与他们连接的氮原子一起形成5至7元含氮杂环基,所述含氮杂环基任选进一步被选自卤素、氧代基、烷基、烷氧基的一个或多个基团取代;
所述烷基优选C1-C12烷基,更优选C1-C6烷基;
所述环烷基优选C3-C12环烷基,更优选C3-C6环烷基;
所述5至7元含氮杂环基优选吡咯烷基、四氢咪唑基、四氢吡唑基、四氢噁唑基、四氢噻唑基、哌啶基、哌嗪基、吗啉基。
在本发明另一个优选的实施方案中,根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其中,
n是0;
R3选自氢、烷基、环烷基;
R4和R5各自独立地选自氢、烷基,其中所述烷基任选进一步被选自杂环基的一个或多个基团取代;所述杂环基任选进一步被卤素或烷基取代;
所述烷基优选C1-C12烷基,更优选C1-C6烷基;
所述环烷基优选C3-C12环烷基,更优选C3-C6环烷基;
所述杂环基优选3至8元杂环基,更优选四氢呋喃基、四氢噻吩基、四氢噁唑基、四氢噻唑基。
在本发明另一个优选的实施方案中,根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其为通式II所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中:
W选自N或CR1;
R1选自氢、卤素、氰基、烷基;
A选自N或CRc;
Rc选自氢、卤素、氰基、烷基、烷氧基、卤代烷基、卤代烷氧基;
X选自-O-、-S-、-NR2-;
R2选自氢、烷基、环烷基;
n是0;
R3选自氢、烷基、环烷基;
R4和R5各自独立地选自氢、烷基,其中所述烷基任选进一步被选自-NRaRb的一个或多个基团取代;
Ra和Rb各自独立地选自氢、烷基、环烷基;
或者Ra和Rb与他们连接的氮原子一起形成5至7元含氮杂环基;
所述烷基优选C1-C12烷基,更优选C1-C6烷基;
所述烷氧基优选C1-C12烷氧基,更优选C1-C6烷氧基;
所述环烷基优选C3-C12环烷基,更优选C3-C6环烷基;
所述5至7元含氮杂环基优选吡咯烷基、四氢咪唑基、四氢吡唑基、四氢噁唑基、四氢噻唑基、哌啶基、哌嗪基、吗啉基。
Cy、L1、L2、R7如通式I中所定义。
在本发明另一个优选的实施方案中,根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其为通式III所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,
W选自N或CR1;
R1选自氢、卤素、氰基、烷基;
A选自N或CRc;
Rc选自氢、卤素、氰基、烷基、烷氧基、卤代烷基、卤代烷氧基;
X选自-O-、-S-、-NR2;
R2选自氢、烷基、环烷基;
n是0;
R3选自氢、烷基、环烷基;
R4和R5各自独立地选自氢、烷基,其中所述烷基任选进一步被选自-NRaRb的一个或多个基团取代;
Ra和Rb各自独立地选自氢、烷基、环烷基;
或者Ra和Rb与他们连接的氮原子一起形成5至7元含氮杂环基;
E选自N或CRd;
Rd选自氢、卤素、氰基、烷基、烷氧基、卤代烷基、卤代烷氧基;
R9选自氢、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基;
L1和L2各自独立地选自单键、-(CH2)m-、-O-、-NR6-、-S-、-SO-、-SO2-和-CO-中的一种或多种;优选-L1-L2-选自单键、-(CH2)m-、-O-、-NR6-、-S-、-SO-、-SO2-、-CO-、-NH-CO-、-NH-SO2-、-CH2-O-、-CH2-S-、-CH2-CO-、-CH2-SO2-、-NR6-(CH2)m-NR6、-O-(CH2)m-O-、-CH2-NR6-、或-CO-NR6-;
m是1至4的整数;
R6选自氢、烷基、环烷基;
R7选自烷基、环烷基、杂环基;其中所述烷基、环烷基、杂环基任选进一步被一个或多个R8取代;
每个R8各自独立地选自卤素、氰基、氧代基、烷基、烷氧基、-C(O)Ra、-C(O)ORa、-S(O)Ra、-S(O)2Ra;其中所述烷基、烷氧基任选进一步被卤素取代;
Ra选自氢、烷基;
所述烷基优选C1-C12烷基,更优选C1-C6烷基;
所述烷氧基优选C1-C12烷氧基,更优选C1-C6烷氧基;
所述环烷基优选C3-C12环烷基,更优选C3-C6环烷基;
W、X、A、Z如通式II中所定义。
在本发明另一个优选的实施方案中,根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其为通式IV所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
W选自N或CR1;
R1选自氢、卤素、氰基、烷基;
X选自-O-、-NR2-和-S-;
R2选自氢、烷基、环烷基;
A选自N或CRc;
Rc选自氢、卤素、氰基、烷基、烷氧基、卤代烷基;
R3选自氢、烷基、环烷基;
R9选自氢、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基;
L1和L2各自独立地选自单键、-(CH2)m-、-O-、-NR6-、-S-、-SO-、-SO2-和-CO-中的一种或多种;
m是1至4的整数;
R6选自氢、烷基、环烷基;
R7选自烷基、环烷基、杂环基;其中所述烷基、环烷基、杂环基任选进一步被一个或多个R8取代;
每个R8各自独立地选自卤素、氧代基、烷基、-COOH,所述烷基任选进一步被卤素取代;
其中,-L1-L2-优选自单键、-(CH2)m-、-O-、-NR6-、-S-、-SO-、-SO2-、-CO-、-NH-CO-、-NH-SO2-、-CH2-O-、-CH2-S-、-CH2-CO-、-CH2-SO2-、-NR6-(CH2)m-NR6、-O-(CH2)m-O-、-CH2-NR6-、或-CO-NR6-;
本发明典型的化合物包括,但不限于:
N-(3-((5-氯-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺;
N-(3-((5-氟-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺;
N-(3-((5-氰基-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺;
N-(3-((5-甲基-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺;
N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺;
4-(二甲氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺;
4-(二甲氨基)-N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺;
4-(环丙基(甲基)氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)-4-(吡咯烷-1-基)丁-2-烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)硫)苯基)丙烯酰胺;
N-(3-(甲基(6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-甲基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-甲基-N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-环丙基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(2-氟-5-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(4-((6-(4-吗啉苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)吡啶-2-基)丙烯酰胺;
N-(2-甲基-5-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(2-甲氧基-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(2-氰基-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(6-(4-甲基哌嗪-1-基)吡啶-3-基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-氟-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-甲氧基-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-甲基-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-(二氟甲氧基)-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(二甲氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((二甲氨基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(2-甲氧基乙氧基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(1,1-二氧代硫代吗啉基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4-(2,2,2-三氟乙基)哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(6-甲基-2,6-二氮杂螺[3.3]庚烷-2-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(2-硫代-6-氮杂螺[3.3]庚烷-6-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4-乙酰基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(2,4-二甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
1-(4-(4-(3-丙烯酰氨基苯氧基)-7H-吡咯并[2,3-d]嘧啶-6-基)苯基)-4-甲基哌嗪-2-羧酸;
N-(3-((6-(4-(4,4-二氟哌啶-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-(3-((6-(4-(吗啉基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(哌啶-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(吡咯烷-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((6-甲基-2,6-二氮杂螺[3.3]庚烷-2-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((3-甲基-3,8-二氮杂双环[3.2.1]辛烷-8-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((1-甲基哌啶-4-基)氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(吗啉-4-甲酰基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((1-甲基哌啶-4-基)氧)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(甲基(1-甲基哌啶-4-基)氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((4-甲基哌嗪-1-基)磺酰基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(((1-甲基哌啶-4-基)氧)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(((1-甲基哌啶-4-基)氨基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((甲基(1-甲基哌啶-4-基)氨基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(4-(4-(3-丙烯酰氨基苯氧基)-7H-吡咯并[2,3-d]嘧啶-6-基)苯基)-1-甲基哌啶-4-甲酰胺;
N-(3-((6-(4-(4-(乙基磺酰基)哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺;
N-(3-((6-(4-(哌啶-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-炔酰胺;
或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐。
本发明另一方面提供一种制备根据本发明所述的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐的方法,该方法包括以下步骤:
1)当W为N时,
步骤a)在高温碱性条件下,在催化剂作用下,将化合物Ia与相应的硼酸类化合物反应得到化合物Ib,所述碱试剂优选碳酸钾或碳酸钠,所述催化剂优选Pd(dppf)Cl2或Pd(PPh3)4,所述温度优选80-100℃;
步骤b)在高温碱性条件下,将化合物Ib与H-X-Y-Z反应得到化合物Ic,所述碱试剂优选碳酸钾,所述温度优选80-120℃;
步骤c)化合物Ic先经酸性条件再经氨水处理后得到通式I化合物,所述酸试剂优选三氟乙酸;
2)当W为CR1时,
步骤d)在高温条件下,将化合物Id与ICl反应得到碘代产物Ie,所述温度优选40℃;
步骤e)在碱性条件下,在催化剂作用下,将化合物Ie与相应的炔类化合物发生Sonogashina偶联反应得到化合物If,所述碱试剂优选三乙胺,所述催化剂优选Pd(Ph3P)2Cl2和CuI;
步骤f)在高温碱性条件下,将化合物If发生关环反应得到化合物Ig,所述碱试剂优选叔丁醇钾,所述温度优选70℃;
步骤g)在碱性条件下,将化合物Ig与SEMCl反应得到化合物Ih,所述碱试剂优选NaH;
步骤h)在高温碱性条件下,将化合物Ih与H-X-Y-Z反应得到化合物Ij,所述碱试剂优选碳酸钾,所述温度优选80-120℃;
步骤i)化合物Ij先经酸性条件再经氨水处理后得到通式I化合物,所述酸试剂优选三氟乙酸;
其中W、X、Y、Z、Cy、L1、L2、R1、R7如通式I中所定义。
本发明的另一方面涉及一种药物组合物,其含有有效剂量的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐以及药学上可接受的载体、稀释剂或赋形剂。本发明还涉及一种制备上述组合物的方法,其包括将通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐与药学上可接受的载体、稀释剂或赋形剂相混合。
本发明进一步涉及通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐或包含其的药物组合物,在制备BTK激酶抑制剂中的用途。
本发明进一步涉及通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐或包含其的药物组合物,在制备预防和/或治疗与BTK激酶活性相关的疾病的药物中的用途。所述与BTK活性相关的疾病可以选自炎症、自身免疫性疾病、或癌症,其中所述炎症例如关节炎特别是类风湿性关节炎、银屑病性关节炎、炎症性肠炎、葡萄膜炎;所述自身免疫性疾病例如多发性硬化症、狼疮、银屑病、结节病;所述癌症例如乳腺癌、宫颈癌、结肠癌、肺癌、胃癌、直肠癌、胰腺癌、脑癌、皮肤癌、口腔癌、前列腺癌、骨癌、肾癌、卵巢癌、膀胱癌、肝癌、输卵管肿瘤、卵巢瘤、腹膜肿瘤、黑色素瘤、实体瘤、神经胶质瘤、神经胶母细胞瘤、肝细胞癌、乳突肾性瘤、头颈部肿瘤、白血病、淋巴瘤、骨髓瘤和非小细胞肺癌。
本发明还涉及通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐或包含其的药物组合物,其用作BTK激酶抑制剂的用途。
本发明进一步涉及通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐或包含其的药物组合物,其用作预防和/或治疗与BTK活性相关的疾病的药物的用途。所述与BTK活性相关的疾病可以选自炎症、自身免疫性疾病、或癌症,其中所述炎症例如关节炎特别是类风湿性关节炎、银屑病性关节炎、炎症性肠炎、葡萄膜炎;所述自身免疫性疾病例如多发性硬化症、狼疮、银屑病、结节病;所述癌症例如乳腺癌、宫颈癌、结肠癌、肺癌、胃癌、直肠癌、胰腺癌、脑癌、皮肤癌、口腔癌、前列腺癌、骨癌、肾癌、卵巢癌、膀胱癌、肝癌、输卵管肿瘤、卵巢瘤、腹膜肿瘤、黑色素瘤、实体瘤、神经胶质瘤、神经胶母细胞瘤、肝细胞癌、乳突肾性瘤、头颈部肿瘤、白血病、淋巴瘤、骨髓瘤和非小细胞肺癌。
本发明进一步涉及一种抑制BTK激酶的方法,其包括向需要其的患者施用治疗有效剂量的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐或包含其的药物组合物。
本发明进一步涉及一种预防和/或治疗与BTK活性相关的疾病的方法,其包括向需要其的患者施用治疗有效剂量的通式I所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐或包含其的药物组合物。所述与BTK活性相关的疾病可以选自炎症、自身免疫性疾病、或癌症,其中所述炎症例如关节炎特别是类风湿性关节炎、银屑病性关节炎、炎症性肠炎、葡萄膜炎;所述自身免疫性疾病例如多发性硬化症、狼疮、银屑病、结节病;所述癌症例如乳腺癌、宫颈癌、结肠癌、肺癌、胃癌、直肠癌、胰腺癌、脑癌、皮肤癌、口腔癌、前列腺癌、骨癌、肾癌、卵巢癌、膀胱癌、肝癌、输卵管肿瘤、卵巢瘤、腹膜肿瘤、黑色素瘤、实体瘤、神经胶质瘤、神经胶母细胞瘤、肝细胞癌、乳突肾性瘤、头颈部肿瘤、白血病、淋巴瘤、骨髓瘤和非小细胞肺癌。
按照本发明所属领域的常规方法,本发明通式I所示的化合物可以与酸生成药学上可接受的酸式加成盐。所述酸包括无机酸和有机酸,特别优选盐酸、氢溴酸、硫酸、磷酸、甲磺酸、乙磺酸、对甲苯磺酸、苯磺酸、萘二磺酸、乙酸、丙酸、乳酸、三氟乙酸、马来酸、柠檬酸、富马酸、草酸、酒石酸、苯甲酸等。
此外,本发明还包括本发明通式I所示的化合物的前药。本发明所述的前药是通式I所示的化合物的衍生物,它们自身可能具有较弱的活性甚至没有活性,但是在给药后,在生理条件下(例如通过代谢、溶剂分解或另外的方式)被转化成相应的生物活性形式。
含活性成分的药物组合物可以是适用于口服的形式,例如片剂、糖锭剂、锭剂、水或油混悬液、可分散粉末或颗粒、乳液、硬或软胶囊,或糖浆剂或酏剂。可按照本领域任何已知制备药用组合物的方法制备口服组合物,此类组合物可含有一种或多种选自以下的成分:甜味剂、矫味剂、着色剂和防腐剂,以提供悦目和可口的药用制剂。片剂含有活性成分和用于混合的适宜制备片剂的无毒的可药用的赋形剂。这些赋形剂可以是惰性赋形剂,如碳酸钙、碳酸钠、乳糖、磷酸钙或磷酸钠;造粒剂和崩解剂,例如微晶纤维素、交联羧甲基纤维素钠、玉米淀粉或藻酸;粘合剂,例如淀粉、明胶、聚乙烯吡咯烷酮或阿拉伯胶;和润滑剂,例如硬脂酸镁、硬脂酸或滑石粉。这些片剂可以不包衣或可通过掩盖药物的味道或在胃肠道中延迟崩解和吸收,因而在较长时间内提供缓释作用的已知技术将其包衣。例如,可使用水溶性味道掩蔽物质,例如羟丙基甲基纤维素或羟丙基纤维素,或延长时间物质例如乙基纤维素、醋酸丁酸纤维素。
也可用其中活性成分与惰性固体稀释剂例如碳酸钙、磷酸钙或高岭土混合的硬明胶胶囊,或其中活性成分与水溶性载体例如聚乙二醇或油溶媒例如花生油、液体石蜡或橄榄油混合的软明胶胶囊提供口服制剂。
水悬浮液含有活性物质和用于混合的适宜制备水悬浮液的赋形剂。此类赋形剂是悬浮剂,例如羧基甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、藻酸钠、聚乙烯吡咯烷酮和阿拉伯胶;分散剂或湿润剂可以是天然产生的磷脂例如卵磷脂,或烯化氧与脂肪酸的缩合产物例如聚氧乙烯硬脂酸酯,或环氧乙烷与长链脂肪醇的缩合产物,例如十七碳亚乙基氧基鲸蜡醇(heptadecaethyleneoxy cetanol),或环氧乙烷与由脂肪酸和己糖醇衍生的部分酯的缩合产物,例如聚环氧乙烷山梨醇单油酸酯,或环氧乙烷与由脂肪酸和己糖醇酐衍生的偏酯的缩合产物,例如聚环氧乙烷脱水山梨醇单油酸酯。水混悬液也可以含有一种或多种防腐剂例如尼泊金乙酯或尼泊金正丙酯、一种或多种着色剂、一种或多种矫味剂和一种或多种甜味剂,例如蔗糖、糖精或阿司帕坦。
油混悬液可通过使活性成分悬浮于植物油如花生油、橄榄油、芝麻油或椰子油,或矿物油例如液体石蜡中配制而成。油悬浮液可含有增稠剂,例如蜂蜡、硬石蜡或鲸蜡醇。可加入上述的甜味剂和矫味剂,以提供可口的制剂。可通过加入抗氧化剂例如丁羟茴醚或α-生育酚保存这些组合物。
通过加入水可使适用于制备水混悬也的可分散粉末和颗粒提供活性成分和用于混合的分散剂或湿润剂、悬浮剂或一种或多种防腐剂。适宜的分散剂或湿润剂和悬浮剂可说明上述的例子。也可加入其他赋形剂例如甜味剂、矫味剂和着色剂。通过加入抗氧化剂例如抗坏血酸保存这些组合物。
本发明的药物组合物也可以是水包油乳剂的形式。油相可以是植物油例如橄榄油或花生油,或矿物油例如液体石蜡或其混合物。适宜的乳化剂可以是天然产生的磷脂,例如大豆卵磷脂和由脂肪酸和己糖醇酐衍生的酯或偏酯例如山梨坦单油酸酯,和所述偏酯和环氧乙烷的缩合产物,例如聚环氧乙烷山梨醇单油酸酯。乳剂也可以含有甜味剂、矫味剂、防腐剂和抗氧剂。可用甜味剂例如甘油、丙二醇、山梨醇或蔗糖配制糖浆和酏剂。此类制剂也可含有缓和剂、防腐剂、着色剂和抗氧剂。
药物组合物可以是无菌注射水溶液形式。可在使用的可接受的溶媒和溶剂中有水、林格氏液和等渗氯化钠溶液。无菌注射制剂可以是其中活性成分溶于油相的无菌注射水包油微乳。例如将活性成分溶于大豆油和卵磷脂的混合物中。然后将油溶液加入水和甘油的混合物中处理形成微乳。可通过局部大量注射,将注射液或微乳注入患者的血流中。或者,最好按可保持本发明化合物恒定循环浓度的方式给予溶液和微乳。为保持这种恒定浓度,可使用连续静脉内递药装置。这种装置的实例是Deltec CADD-PLUS.TM.5400型静脉注射泵。
药物组合物可以是用于肌内和皮下给药的无菌注射水或油混悬液的形式。可按已知技术,用上述那些适宜的分散剂或湿润剂和悬浮剂配制该混悬液。无菌注射制剂也可以是在无毒肠胃外可接受的稀释剂或溶剂中制备的无菌注射溶液或混悬液,例如1,3-丁二醇中制备的溶液。此外,可方便地用无菌固定油作为溶剂或悬浮介质。为此目的,可使用包括合成甘油单或二酯在内的任何调和固定油。此外,脂肪酸例如油酸也可以制备注射剂。
可按用于直肠给药的栓剂形式给予本发明化合物。可通过将药物与在普通温度下为固体但在直肠中为液体,因而在直肠中会溶化而释放药物的适宜的无刺激性赋形剂混合来制备这些药物组合物。此类物质包括可可脂、甘油明胶、氢化植物油、各种分子量的聚乙二醇和聚乙二醇的脂肪酸酯的混合物。
本领域技术人员所熟知的,药物的给药剂量依赖于多种因素,包括但并非限定以下因素:所用特定化合物的活性、病人的年龄、病人的体重、病人的健康状况、病人的行被、病人的饮食、给药时间、给药方式、排泄的速率、药物的组合等;另外,最佳的治疗方式如治疗的模式、通式化合物的日用量或可药用的盐的种类可以根据传统的治疗方案来验证。
本发明可以含有通式I的含有吡咯并芳杂环骨架的化合物,及其药学上可接受的盐、水合物或溶剂化物作为活性成份,与药学上可接受的载体或赋型剂混合制备成组合物,并制备成临床上可接受的剂型。本发明的衍生物可以与其他活性成分组合使用,只要它们不产生其他不利的作用,例如过敏反应等。本发明化合物可作为唯一的活性成分,也可以与其它治疗与BTK活性相关的疾病的药物联合使用。联合治疗通过将各个治疗组分同时、分开或相继给药来实现。
本发明通过BTK活性试验,发现本发明化合物具有显著的调节BTK激酶的活性,因此本发明化合物可以用于治疗和/或预防与BTK的活性相关的疾病,例如炎症、自身免疫性病症、癌症或其它疾病。特别用于制备治疗和/或预防类风湿性关节炎、银屑病、和/或涉及软骨退化、骨关节退化的疾病。
发明的详细说明
除非有相反陈述,在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团,其为包含1至20个碳原子的直链或支链基团,优选含有1至12个碳原子的烷基,更优选含有1至6个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基,及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基,非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“烯基”指由至少由两个碳原子和至少一个碳-碳双键组成的如上定义的烷基,例如乙烯基、1-丙烯基、2-丙烯基、1-、2-或3-丁烯基等。烯基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“炔基”指由至少由两个碳原子和至少一个碳-碳三键组成的如上定义的烷基,例如乙炔基、丙炔基、丁炔基等。炔基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基,环烷基环包含3至20个碳原子,优选包含3至12个碳原子,更优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等;多环环烷基包括螺环、稠环和桥环的环烷基。
术语“螺环烷基”指5至20元的单环之间共用一个碳原子(称螺原子)的多环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据环与环之间共用螺原子的数目将螺环烷基分为单螺环烷基、双螺环烷基或多螺环烷基,优选为单螺环烷基和双螺环烷基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺环烷基。螺环烷基的非限制性实例包括:
术语“稠环烷基”指5至20元,系统中的每个环与体系中的其他环共享毗邻的一对碳原子的全碳多环基团,其中一个或多个环可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠环烷基,优选为双环或三环,更优选为5元/5元或5元/6元双环烷基。稠环烷基的非限制性实例包括:
术语“桥环烷基”指5至20元,任意两个环共用两个不直接连接的碳原子的全碳多环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥环烷基,优选为双环、三环或四环,更有选为双环或三环。桥环烷基的非限制性实例包括:
所述环烷基环可以稠合于芳基、杂芳基或杂环烷基环上,其中与母体结构连接在一起的环为环烷基,非限制性实例包括茚满基、四氢萘基、苯并环庚烷基等。环烷基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基,其包含3至20个环原子,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳。优选包含3至12个环原子,其中1~4个是杂原子;最优选包含3至8个环原子,其中1~3个是杂原子;最优选包含5至7个环原子,其中1~2或1~3个是杂原子。单环杂环基的非限制性实例包括吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、吡喃基等,优选1、2、5-噁二唑基、吡喃基或吗啉基。多环杂环基包括螺环、稠环和桥环的杂环基。
术语“螺杂环基”指5至20元的单环之间共用一个原子(称螺原子)的多环杂环基团,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基、双螺杂环基或多螺杂环基,优选为单螺杂环基和双螺杂环基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环基。螺杂环基的非限制性实例包括:
术语“稠杂环基”指5至20元,系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团,一个或多个环可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基,优选为双环或三环,更优选为5元/5元或5元/6元双环稠杂环基。稠杂环基的非限制性实例包括:
术语“桥杂环基”指5至14元,任意两个环共用两个不直接连接的原子的多环杂环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥杂环基,优选为双环、三环或四环,更有选为双环或三环。桥杂环基的非限制性实例包括:
所述杂环基环可以稠合于芳基、杂芳基或环烷基环上,其中与母体结构连接在一起的环为杂环基,其非限制性实例包括:
杂环基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至10元,例如苯基和萘基。更优选苯基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为芳基环,其非限制性实例包括:
芳基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系,其中杂原子选自氧、硫和氮。杂芳基优选为5至10元,含1至3个杂原子;更优选为5元或6元,含1至2个杂原子;优选例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等,优选为咪唑基、噻唑基、吡唑基或嘧啶基、噻唑基;更有选吡唑基或噻唑基。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为杂芳基环,其非限制性实例包括:
杂芳基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基),其中烷基的定义如上所述。烷氧基的非限制性实例包括:甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“卤代烷基”指被一个或多个卤素取代的烷基,其中烷基如上所定义。
术语“卤代烷氧基”指被一个或多个卤素取代的烷氧基,其中烷氧基如上所定义。
术语“羟烷基”指被羟基取代的烷基,其中烷基如上所定义。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH2。
术语“氰基”指-CN。
术语“硝基”指-NO2。
术语“氧代基”指=O。
术语“羧基”指-C(O)OH。
术语“巯基”指-SH。
术语“酯基”指-C(O)O(烷基)或-C(O)O(环烷基),其中烷基和环烷基如上所定义。
术语“酰基”指含有-C(O)R基团的化合物,其中R为烷基、环烷基、杂环基、芳基、杂芳基。
术语“磺酸基”指-S(O)2OH。
术语“磺酸酯基”指-S(O)2O(烷基)或-S(O)2O(环烷基),其中烷基和环烷基如上所定义。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生,该说明包括该事件或环境发生或不发生的场合。例如,“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在,该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子,优选为最多5个,更优选为1~3个氢原子彼此独立地被相应数目的取代基取代。不言而喻,取代基仅处在它们的可能的化学位置,本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如,具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物,以及其他组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。
“可药用盐”是指本发明化合物的盐,这类盐用于哺乳动物体内时具有安全性和有效性,且具有应有的生物活性。
本发明化合物的合成方法
为了完成本发明的目的,本发明采用如下技术方案。
本发明通式I所示的化合物或其盐的制备方法如下。
1)当W为N时,可以按照方案1的方法,由化合物Ia作为起始原料经Suzuki反应、偶联和脱保护反应得到通式I化合物。
方案1
方案1的合成:
在高温碱性条件下,在催化剂作用下,将化合物Ia与相应的硼酸或硼酸频哪醇酯类化合物反应得到化合物Ib,所述碱试剂优选碳酸钾或碳酸钠,所述催化剂优选Pd(dppf)Cl2或Pd(PPh3)4,所述温度优选80-100℃;随后,在高温碱性条件下,将化合物Ib与H-X-Y-Z反应得到化合物Ic,所述碱试剂优选碳酸钾,所述温度优选80-120℃;最后,化合物Ic先经酸性条件再经氨水处理后得到通式I化合物,所述酸试剂优选三氟乙酸。
2)当W为CR1时,可以按照方案2的方法,由Id作为起始原料经碘代反应、Sonogashina偶联反应、关环反应、SEM保护、偶联和脱保护反应得到通式I化合物。
方案2
方案2的合成:
在高温条件下,将化合物Id与ICl反应得到碘代产物Ie,所述温度优选40℃;随后,在碱性条件下,在催化剂作用下,将化合物Ie与相应的炔类化合物发生Sonogashina偶联反应得到化合物If,所述碱试剂优选三乙胺,所述催化剂优选Pd(Ph3P)2Cl2和CuI;随后,在高温碱性条件下,将化合物If发生关环反应得到化合物Ig,所述碱试剂优选叔丁醇钾,所述温度优选70℃;随后,在碱性条件下,将化合物Ig与SEMCl反应得到化合物Ih,所述碱试剂优选NaH;随后,在高温碱性条件下,将化合物Ih与H-X-Y-Z反应得到化合物Ij,所述碱试剂优选碳酸钾,所述温度优选80-120℃;最后,化合物Ij先经酸性条件再经氨水处理后得到通式I化合物,所述酸试剂优选三氟乙酸。
具体实施方式
以下结合实施例进一步描述本发明,但这些实施例并非限制着本发明的范围。
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移以10-6(ppm)的单位给出。NMR的测定是用Brukerdps300型核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d6),氘代氯仿(CDCl3),氘代甲醇(CD3OD),内标为四甲基硅烷(TMS)。
MS的测定用1100 Series LC/MSD Trap(ESI)质谱仪(生产商:Agilent,)。
制备液相使用lc3000高效液相色谱仪以及lc6000高效液相色谱仪(生产商:创新通恒)
HPLC的测定使用岛津LC-20AD高压液相色谱仪(Agilent TC-C18 250×4.6mm 5vm色谱柱)和岛津LC-2010AHT高压液相色谱仪(Phenomenex C18 250×4.6mm5um色谱柱)。
激酶平均抑制率及IC50值的测定用多功能Cytation3酶标仪(美国Bioteck公司)。
薄层层析硅胶板使用青岛海洋化工GF254硅胶板,薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm~0.2mm,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm。
柱层析一般使用青岛海洋硅胶100~200目、200~300目硅胶为载体。
本发明的已知的起始原料可以采用或按照本领域已知的方法来合成,或可购买自网化商城、北京耦合、Sigma、百灵威、易世明、上海书亚、伊诺凯、安耐吉化学等公司。
实施例中无特殊说明,反应能够均在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。
微波反应使用CEM Discover SP型微波反应器。
实施例中无特殊说明,溶液是指水溶液。
实施例中无特殊说明,反应的温度为室温,为20℃~30℃。
实施例中的反应进程的监测采用薄层色谱法(TLC),反应所使用的展开剂的体系有:A:二氯甲烷和甲醇体系,B:正己烷和乙酸乙酯体系,C:石油醚和乙酸乙酯体系,D:丙酮,溶剂的体积比根据化合物的极性不同而进行调节。
纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂体系包括:A:二氯甲烷和甲醇体系,B:正己烷和乙酸乙酯体系,C:石油醚和乙酸乙酯体系,溶剂的体积比根据化合物的极性不同而进行调节,也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。
实施例1:N-(3-((5-氯-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺的制备
步骤1:4-(4-甲基哌嗪-1-基)苯甲醛的合成(中间体1A)
将4-氟苯甲醛(5g,40mmol)溶于30mL水中,加入N-甲基哌嗪(6.86g,68mmol)和碳酸钠(7.26g,68mmol),反应液加热至100℃搅拌16小时。将反应液冷却至室温,加入100mL水,用二氯甲烷(50mL×3)萃取,合并有机相,用饱和食盐水(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后用正己烷(100mL)打浆,过滤,滤饼用正己烷洗涤,得到7g黄色固体的标题产物,收率:85%。
步骤2:1-(4-乙炔基苯基)-4-甲基哌嗪的合成(中间体1B)
将TMSCH2N2(18mL,36mmol)溶于无水四氢呋喃(50mL),氮气保护下降温至-78℃,缓慢滴加n-BuLi(14.4mL,36mmol),滴加完毕后,继续在-78℃反应1小时。将4-(4-甲基哌嗪-1-基)苯甲醛(6.12g,30mmol)溶于无水四氢呋喃(20mL)缓慢滴加至反应液中,滴加完毕后继续搅拌1小时,然后缓慢升至室温,继续搅拌1小时。向反应液中加入饱和氯化铵溶液(50mL)淬灭反应,加入乙酸乙酯(100mL×2)萃取,合并有机相,再用饱和食盐水(100mL×2)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1~二氯甲烷∶甲醇=10∶1)纯化,得到5g黄色固体状的标题产物,收率:83%。
步骤3:4-溴-5-氯吡啶-2-胺的合成(中间体1C)
将4-溴吡啶-2-胺(17.3g,100mmol)溶于DMF(200mL)中,降温至-20℃,分批加入NCS(14.7g,110mmol),加完后,反应液缓慢升至室温,搅拌24小时。反应结束后,向反应液中加入200mL水,用乙酸乙酯(100mL×3)萃取,合并有机相,在用饱和食盐水(100mL×2)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后,将残余物通过柱层析色谱法(洗脱剂:石油醚∶乙酸乙酯=5∶1~石油醚∶乙酸乙酯=1∶1)纯化,得到15g黄色固体状的标题产物,收率:72%。
步骤4:4-溴-5-氯-3-碘吡啶-2-胺的合成(中间体1D)
将4-溴-5-氯吡啶-2-胺(15g,72mmol)溶于DMF(200mL)中,升温至40℃,加入ICl(12.2g,75mmol),继续搅拌4小时,再补加ICl(13g,80mmol),加完后继续搅拌4小时,再补加ICl(10.0g,62mmol),加完后继续搅拌24小时。反应完全后,冷却至室温,向反应液中加入水(200mL),再加入二氯甲烷(200mL×3)萃取,合并有机相,再用硫代硫酸钠水溶液(100mL×3)和饱和食盐水(100mL×2)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后,将残余物通过柱层析色谱法(洗脱剂:石油醚∶乙酸乙酯=5∶1~石油醚∶乙酸乙酯=1∶1)纯化,得到12g棕黄色固体状的标题产物,收率:50%。
步骤5:4-溴-5-氯-3-((4-(4-甲基哌嗪-1-基)苯基)乙炔基)吡啶-2-胺的合成(中间体1E)
将4-溴-5-氯-3-碘吡啶-2-胺(5g,15mmol)溶于DMF(50mL)中,加入1-(4-乙炔基苯基)-4-甲基哌嗪(3g,15mmol)、Pd(Ph3P)2Cl2(1.05g,1.5mmol)、碘化亚铜(570mg,3mmol)和三乙胺(50mL),加完后用氮气置换三次,在氮气保护下室温搅拌24小时。反应完全后,向反应液中加入水(200mL),用二氯甲烷(100mL×3)萃取,合并有机相,用饱和食盐水(100mL×2)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1~二氯甲烷∶甲醇=10∶1)纯化,得到3g棕黄色固体状的标题产物,收率:50%。
步骤6:4-溴-5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡咯并[2,3-b]吡啶的合成(中间体1F)
将4-溴-5-氯-3-((4-(4-甲基哌嗪-1-基)苯基)乙炔基)吡啶-2-胺(3g,7.4mmol)溶于NMP(50mL)中,分批加入叔丁醇钾(1.0g,8.9mmol),加完后,升温至70℃反应5小时。反应完毕后,加入饱和氯化铵溶液(20mL)淬灭,用乙酸乙酯(100mL×3)萃取,合并有机相,再用饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1~二氯甲烷∶甲醇=10∶1)纯化,得到1.5g棕黄色固体状的标题产物,收率:50%。
步骤7:4-溴-5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1-((2-(三甲基硅基)乙氧基)甲基)-1H-吡咯并[2,3-b]吡啶的合成(中间体1G)
将4-溴-5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡咯并[2,3-b]吡啶(1.5g,3.7mmol)溶于无水四氢呋喃(50mL)中,降温至0℃,加入NaH(0.22g,5.5mmol),反应液在0℃继续搅拌1小时,然后加入SEMCl(0.74g,4.4mmol),加入完毕后,缓慢升至室温,继续搅拌2小时。反应完全后,加入饱和氯化铵溶液(20mL)淬灭,用乙酸乙酯(50mL×3)萃取,合并有机相,再用饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后,将残余物通过柱层析色谱法(洗脱剂:石油醚∶乙酸乙酯=5∶1~石油醚∶乙酸乙酯=1∶1)纯化,得到1.2g黄色油状物的标题产物,收率:60%。
步骤8:3-((5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1-((2-(三甲基硅基)乙氧基)甲基)-1H-吡咯并[2,3-b]吡啶-4-基)氧)苯胺的合成(中间体1H)
将4-溴-5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1-((2-(三甲基硅基)乙氧基)甲基)-1H-吡咯并[2,3-b]吡啶(0.8g,1.5mmol)溶于甲苯(100mL)中,加入3-氨基苯酚(0.2g,1.8mmol)、Pd2(dba)3(0.137g,0.15mmol)、Xantphos(0.173g,0.3mmol)、K2CO3(0.41g,3mmol),反应液用氮气置换三次,然后在氮气保护下会回流3小时。反应完全后,减压浓缩,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1~二氯甲烷∶甲醇=10∶1)纯化,得到0.6g黄色固体状的标题产物,收率:72%。
步骤9:N-(3-((5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1-((2-(三甲基硅基)乙氧基)甲基)-1H-吡咯并[2,3-b]吡啶-4-基)氧)苯基)丙烯酰胺的合成(中间体1I)
将3-((5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1-((2-(三甲基硅基)乙氧基)甲基)-1H-吡咯并[2,3-b]吡啶-4-基)氧)苯胺(0.6g,1mmol)溶于THF/H2O(30mL/50mL)混合溶液中,降温至0℃,加入NaHCO3(180mg,2mmol),再加入丙烯酰氯(100mg,1mmol),然后在0℃继续搅拌1小时。反应完全后,加入乙酸乙酯(50mL×3)萃取,合并有机相,再用饱和食盐水洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1~二氯甲烷∶甲醇=10∶1)纯化,得到0.5g黄色固体的标题产物,收率:77%。
步骤10:N-(3-((5-氯-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺的合成(化合物1)
将N-(3-((5-氯-2-(4-(4-甲基哌嗪-1-基)苯基)-1-((2-(三甲基硅基)乙氧基)甲基)-1H-吡咯并[2,3-b]吡啶-4-基)氧)苯基)丙烯酰胺(0.5g,0.8mmol)溶于二氯甲烷(15mL)中,加入三氟乙酸(15mL),反应液室温搅拌24小时。反应完全后,减压浓缩,残余物经制备液相纯化,得到30mg淡黄色固体的标题产物,收率:7.9%。
MS:m/z=488.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.39(s,1H),10.20(s,1H),9.73(s,1H),8.27(s,1H),7.72-7.74(m,2H),7.46(m,1H),7.37(m,2H),7.02(m,3H),6.79(m,1H),6.35(m,1H),6.19(m,2H),5.72(m,1H),3.95(m,2H),3.50(m,2H),3.13(m,2H),3.01(m,2H),2.85(s,3H).
实施例2:N-(3-((5-氟-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺的制备
与实施例1的制备方法相同,除了用4-溴-5-氟吡啶-2-胺替代4-溴-5-氯吡啶-2-胺(中间体1C),得到标题化合物
MS:m/z=471.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.51(s,1H),10.33(s,1H),8.29(s,1H),7.69-7.78(m,2H),7.40(m,1H),7.33(m,1H),6.94-7.03(m,3H),6.80(m,1H),6.41(m,1H),6.24(m,2H),5.70(m,1H),3.72(m,4H),3.14(m,2H),2.99(m,2H),2.87(s,3H).
实施例3:N-(3-((5-氰基-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺的制备
与实施例1的制备方法相同,除了用6-氨基-4-溴烟氰替代4-溴-5-氯吡啶-2-胺(中间体1C),得到标题化合物
MS:m/z=479.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.55(s,1H),10.33(s,1H),8.41(s,1H),7.80(m,2H),7.50(m,1H),7.39(m,2H),7.10(m,3H),6.85(m,1H),6.39(m,1H),6.21(m,2H),5.75(m,1H),3.78(m,4H),3.13(m,4H),2.85(s,3H).
实施例4:N-(3-((5-甲基-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺的制备
与实施例1的制备方法相同,除了用4-溴-5-甲基吡啶-2-胺替代4-溴-5-氯吡啶-2-胺(中间体1C),得到标题化合物
MS:m/z=479.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.69(s,1H),10.51(s,1H),8.10(s,1H),7.66-7.74(m,2H),7.40(m,1H),7.35(m,2H),6.97(m,3H),6.76(m,1H),6.33(m,1H),6.20(m,2H),5.70(m,1H),3.93-3.99(m,2H),3.46-3.53(m,2H),3.13(m,2H),2.99(m,2H),2.90(s,3H).
实施例5:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺的制备
步骤1:6-溴-4-氯-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶的合成(中间体5A)
将6-溴-4-氯-7H-吡咯并[2,3-d]嘧啶(购自网化商城)1.1g(4.72mmol)溶解于40mL THF中,并将得到的溶液冷却至0-5℃,然后向其中加入283mg(7.08mmol)NaH,于该温度搅拌反应液1小时,然后加入SEM-Cl 1.2g(7.08mmol),继续搅拌反应液3小时。用40mL饱和氯化铵溶液淬灭反应,然后用40mL二氯甲烷萃取,有机相用40mL饱和食盐水洗涤,并用无水硫酸钠干燥,过滤,滤液减压浓缩,将残余物通过柱层析色谱法(洗脱剂:石油醚∶乙酸乙酯=20∶1~石油醚∶乙酸乙酯=5∶1)纯化,得到900mg白色固体状的标题产物,收率:52.6%。
步骤2:4-氯-6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶的合成(中间体5B)
将6-溴-4-氯-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶(900mg,2.48mmol)加入至100mL反应瓶中,向其中依次加入(4-(4-甲基哌嗪-1-基)苯基)硼酸(491mg,2.23mmol)、二氧六环50mL、碳酸钠(632mg,5.96mmol)、水5mL、Pd(dppf)Cl2(100mg,0.14mmol)。在氩气保护下,将混合物加热至80℃并搅拌反应4小时。将反应液冷却至室温,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯)纯化,得到600mg棕色油状物的标题产物,收率:52.8%。
步骤3:N1-(6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)苯-1,3-二胺的合成(中间体5C)
氮气保护下,将4-氯-6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶(600mg,1.31mmol)、间苯二胺(284mg,2.62mmol)、TsOH(226mg,1.31mmol)、n-BuOH 25mL依次加到反应瓶中,将混合物加热至100℃反应2小时。将反应液减压浓缩旋干,将残余物通过柱层析色谱法(洗脱剂:甲醇∶二氯甲烷=1∶20)纯化,得450mg标题产物,收率:52.8%。
步骤4:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶哌啶-4-基)氨基)苯基)丙烯酰胺的合成(中间体5D)
将N-(6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)苯-1,3-二胺(450mg,0.76mmol)溶解于30mL二氯甲烷中,并加入三乙胺156mg(1.52mmol),将反应液冷却至0-5℃,然后向其中缓慢滴加丙烯酰氯75mg(0.83mmol)在10mL二氯甲烷中的溶液,滴加完毕后保持0-5℃搅拌1小时。反应结束后,向反应液中加入40mL水淬灭,有机相用50mL饱和食盐水洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,得520mg粗产物,其未经纯化直接用于下步反应。
步骤5:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺的合成(化合物5)
将N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶哌啶-4-基)氨基)苯基)丙烯酰胺520mg(0.89mmol)加入至50mL反应瓶中,并向其中加入二氯甲烷5mL、三氟乙酸5mL,将反应液室温搅拌过夜,然后减压浓缩至干。向残余物中加入甲醇20mL和氨水3mL,室温搅拌3小时。反应完毕后,向反应液中加入10mL饱和食盐水,20mL二氯甲烷萃取,有机相减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=10∶1)纯化,得120mg浅黄色固体标题产物,收率:29.7%,纯度95.4%。
MS:m/z=454.6[M+H]+。
1H NMR(300MHz,MeOD):δ8.18(s,1H),8.08(d,1H),7.73(d,2H),7.53(m,2H),7.28(m,1H),7.13(d,2H),6.93(s,1H),6.41(m,2H),5.80(m,1H),3.75(m,4H),3.18(m,4H),2.98(m,3H).
实施例6:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺的制备
步骤1:3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯胺的合成(中间体6A)
将4-氯-6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶1.50g(3.28mmol)加入至50mL反应瓶中,并向其中加入间氨基苯酚0.54g(4.90mmol)、碳酸钾0.90g(6.55mmol)、DMF 15mL,将反应液升温至100℃搅拌过夜。反应完毕后,减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=30∶1)纯化,得1.20g浅黄色油状物标题产物,收率:69.1%,纯度96.4%。
步骤2:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺的合成(中间体6B)
丁-2-炔酰氯的制备:
将2-丁炔酸2.0g(23.8mmol)加入至50mL反应瓶中,并向其中加入THF(20mL),室温搅拌,缓慢滴加草酰氯1.2mL,滴加完后加DMF 3滴,室温搅拌1小时。浓缩至干备用。
将3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯胺1.2g(2.26mmol)加入至50mL反应瓶中,并向其中加入碳酸氢钠0.29g(3.40mmol)、THF 20mL、水4mL,冰浴下搅拌,将上面制备的丁-2-炔酰氯加入到10mL THF中,缓慢滴加到反应瓶中,滴加完后室温搅拌1小时。反应完毕后,加50mL氯化铵饱和水溶液淬灭,加50mL二氯甲烷萃取,有机层加无水硫酸钠干燥,减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1-二氯甲烷∶甲醇=10∶1)纯化,得500mg浅黄色油状物标题产物,收率:37.1%,纯度97.4%。
步骤3:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺的合成(化合物6)
将N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺500mg(0.80mmol)加入至50mL反应瓶中,并向其中加入二氯甲烷5mL、三氟乙酸5mL,将反应液室温搅拌过夜,然后减压浓缩至干。向残余物中加入甲醇3mL和氨水3mL,室温搅拌1小时。反应完毕后,抽滤,滤饼用5mL水洗涤,干燥滤饼,得180mg浅黄色固体标题产物,收率:46.0%,纯度95.3%。
MS:m/z=467.9[M+H]+。
1H NMR(300MHz,DMSO):δ12.53(s,1H),10.77(s,1H),8.26(m,1H),7.80(m,2H),7.56(m,1H),7.42(m,2H),7.01(m,3H),6.83(m,1H),3.33(m,4H),3.24(m,4H),2.26(s,3H),2.05(s,3H).
实施例7:N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺的制备
与实施例6的制备方法相同,除了用3-氨基-4-氟苯酚替代3-氨基苯酚,得到标题化合物。
MS:m/z=485.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.48(s,1H),10.69(s,1H),8.28(m,1H),7.83(m,2H),7.53(m,3H),7.08(m,3H),6.85(m,1H),3.38(m,4H),3.25(m,4H),2.26(s,3H),2.05(s,3H).
实施例8:4-(二甲氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺的制备
步骤1:3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯胺的合成(中间体6A)
将4-氯-6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶3.00g(6.55mmol)加入至50mL反应瓶中,并向其中加入间氨基苯酚1.08g(9.80mmol)、碳酸钾1.80g(13.10mmol)、DMF 30mL,将反应液升温至100℃搅拌过夜。反应完毕后,减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=30∶1)纯化,得2.30g浅黄色油状物标题产物,收率:66.2%,纯度95.7%。
步骤2:(2-((3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)氨基)-2-氧代乙基)膦酸二乙酯的合成(中间体8A)
将N,N′-羰基二咪唑0.93g(5.86mmol)、THF(20mL)加入至50mL反应瓶中,室温搅拌10分钟,将二乙基磷乙酸1.50g(7.66mmol)加到10mLTHF中,缓慢滴加到反应瓶中,然后将3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯胺1.40g(2.64mmol)加到10mL THF中,缓慢滴加到反应瓶中,室温搅拌过夜。反应完毕后,加50mL乙酸乙酯、50mL水洗涤,有机层用饱和氯化钠水溶液洗涤两次,无水硫酸钠干燥,有机相减压浓缩至干,得1.50g棕色固体标题产物,收率:80.2%,纯度95.0%。
步骤3:4-(二甲基氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-1H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-烯酰胺的合成(中间体8B)
(二甲基氨基)乙醛溶液的制备:
将浓盐酸5mL、水2mL加到50mL反应瓶中,加热至40℃搅拌,将N,N-二甲氨基乙醛缩二乙醇加入到反应瓶中,40℃搅拌过夜,备用。
将(2-((3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)氨基)-2-氧代乙基)膦酸二乙酯1.00g(1.40mmol)、DMF 10mL加到50mL反应瓶中,冰浴下搅拌,加入NaH 0.5g(20.83mmol),冰浴下搅拌30分钟,然后将(二甲基氨基)乙醛溶液5mL加到反应瓶中,冰浴下反应1小时。反应完毕后,加50mL水、20mL乙酸乙酯萃取,水层用NaOH水溶液调pH至9~10,加20mL乙酸乙酯萃取,有机相浓缩至干,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=10∶1)纯化,得0.30g黄色固体标题产物,收率:33.1%,纯度98.7%。
步骤4:4-(二甲氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺的合成(化合物8)
将4-(二甲基氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-1H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-烯酰胺300mg(0.47mmol)加入至25mL反应瓶中,并向其中加入二氯甲烷3mL、三氟乙酸3mL,将反应液室温搅拌过夜,然后减压浓缩至干。向残余物中加入甲醇3mL和氨水3mL,室温搅拌1小时。反应完毕后,抽滤,滤饼用5mL水洗涤,干燥滤饼,得110mg浅黄色固体标题产物,收率:46.0%,纯度95.3%。
MS:m/z=512.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.53(s,1H),10.68(s,1H),8.24(m,1H),7.76(m,2H),7.54(m,1H),7.40(m,2H),7.00(m,3H),6.80(m,1H),6.74(m,1H),6.06(m,1H),3.10(m,4H),3.01(m,2H),2.58(m,4H),2.34(m,3H),2.18(s,6H).
实施例9:4-(二甲氨基)-N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺的制备
与实施例8的制备方法相同,用3-氨基-4-氟苯酚替代3-氨基苯酚,得到标题化合物。
MS:m/z=530.1[M+H]+。
1H NMR(300MHz,DMSO):δ12.48(s,1H),10.56(s,1H),8.28(m,1H),7.80(m,2H),7.43(m,2H),7.00(m,3H),6.83(m,1H),6.78(m,1H),6.12(m,1H),3.10(m,4H),3.01(m,2H),2.58(m,4H),2.34(m,3H),2.18(s,6H).
实施例10:4-(环丙基(甲基)氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺的制备
步骤1:4-溴-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺的合成(中间体10A)
将4-溴丁-2-烯酸(164mg,1mmol)加入配有氯化钙干燥管、氩气保护气的三口瓶中,加入无水二氯甲烷(3mL),搅拌溶解,向反应瓶中加入草酰氯(139mg,1.1mmol),再加入一滴无水DMF,继续搅拌反应4-5小时,减压浓缩蒸干,备用。
向反应瓶中依次加入3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯胺(265mg,0.5mmol)和四氢呋喃(10mL),在室温下搅拌15分钟,加入碳酸氢钠(127mg,1.5mmol)和蒸馏水(1mL),将备用的浓缩液溶于1mL四氢呋喃,在0℃下缓慢加入反应瓶中,继续在室温下搅拌20小时。向反应混合物加入二氯甲烷(50mL),用水(40mL×3)洗涤,分得有机层,用无水硫酸钠干燥过夜,过滤,滤液用旋转蒸发器减压浓缩,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=12∶1)纯化,得82mg浅灰黄色固体标题产物,收率:24.3%。
步骤2:4-(环丙基(甲基)氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺的合成(中间体10B)
将4-溴-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺(82mg,0.12mmol)溶于DMF(5mL)中,在冰浴条件下,依次加入N-甲基环丙胺(99mg,1.38mmol)和碘化钾(3.3mg,0.02mmol),反应液在室温下搅拌15小时。向反应液加入二氯甲烷(50mL),用水(40mL×3)洗涤,分得有机层,用无水硫酸钠干燥过夜,过滤,滤液用旋转蒸发器减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=6∶1)纯化,得50mg浅灰黄色固体标题产物,收率:61.0%。。
步骤3:4-(环丙基(甲基)氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)苯基)丁-2-烯酰胺的合成(化合物10)
将4-(环丙基(甲基)氨基)-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-烯酰胺50mg(0.074mmol)加入至25mL反应瓶中,并向其中加入二氯甲烷3mL、三氟乙酸1mL,将反应液室温搅拌过夜,然后减压浓缩至干。向残余物中加入甲醇1mL和氨水1mL,室温搅拌1小时。反应完毕后,抽滤,滤饼用5mL水洗涤,干燥滤饼,得31mg浅黄色固体标题产物,收率:54.3%,纯度95.9%。
MS:m/z=538.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.51(s,1H),10.33(s,1H),8.27(m,1H),7.80(m,2H),7.55(m,3H),6.97(m,3H),6.80(m,2H),6.40(m,1H),3.51(m,4H),3.29(m,2H),3.22(m,4H),2.84(m,4H),2.44(s,3H),2.38(m,3H),1.99(m,1H),0.76(m,4H).
实施例11:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)-4-(吡咯烷-1-基)丁-2-烯酰胺的制备
与实施例10的制备方法相同,除了用四氢吡咯替代N-甲基环丙胺,得到标题化合物。
MS:m/z=538.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.58(s,1H),10.41(s,1H),8.27(m,1H),7.83(m,2H),7.58(m,3H),7.00(m,3H),6.82(m,2H),6.38(m,1H),3.51(m,4H),3.22(m,4H),3.06(m,2H),2.84(m,4H),2.44(s,3H),1.80(m,4H).
实施例12:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
步骤1:N-(3-羟基苯基)丙烯酰胺的合成(中间体12A)
将间氨基苯酚(10.0g,90mmol)、四氢呋喃(200mL)、碳酸氢钠(11.4g,135mmol)和蒸馏水30mL依次加入反应瓶中,冰浴下控制温度在0-10℃,将丙烯酰氯(8.2g,90mmol)在50mL四氢呋喃中的溶液缓慢滴入反应瓶中,滴加完毕后,将反应液升至室温并搅拌反应过夜。反应完毕后,向反应液中加入100mL二氯甲烷、100mL饱和氯化铵溶液萃取。有机相用饱和氯化铵溶液洗涤两次,每次100mL。有机相用无水硫酸钠干燥,过滤,滤液减压浓缩,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=10∶1)纯化,得12g类白色固体状的标题产物,收率:81.7%。
步骤2:4-氯-6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶的合成(中间体5B)
将6-溴-4-氯-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶(900mg,2.48mmol)加入至100mL反应瓶中,向其中依次加入(4-(4-甲基哌嗪-1-基)苯基)硼酸(491mg,2.23mmol)、二氧六环50mL、碳酸钠(632mg,5.96mmol)、水5mL、Pd(dppf)Cl2(100mg,0.14mmol)。在氩气保护下,将混合物加热至80℃并搅拌反应4小时。将反应液冷却至室温,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯)纯化,得到600mg棕色油状物的标题产物,收率:52.8%。
步骤3:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的合成(中间体12B)
将4-氯-6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶1.0g(2.2mmol)、N-(3-羟基苯基)丙烯酰胺0.64g(3.9mmol)、碳酸钾0.8g(5.8mmol)、DMF 10mL依次加入单口瓶中,将混合物加热至100℃并搅拌4小时。然后将反应液冷却至室温,并减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=30∶1)纯化,得到1.0g黄色固体状的标题产物,收率:78%。
步骤4:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的的合成(化合物12)
将N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丙烯酰胺1.0g(1.7mmol)加入至50mL反应瓶中,向其中加入二氯甲烷5mL、三氟乙酸5mL,并室温搅拌过夜。然后将反应液减压浓缩至干,并加入甲醇20ml和氨水3mL,室温搅拌3小时。反应完毕后,向反应液中加入10mL饱和食盐水,20mL二氯甲烷萃取。有机相浓缩至干,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=10∶1)纯化,得到160mg浅黄色固体状的标题产物,收率:20.7%,纯度:95.6%。
MS:m/z=455.3[M+H]+
1H NMR(300MHz,DMSO):δ12.53(s,1H),10.30(s,1H),8.27(m,1H),7.80(m,2H),7.68(m,1H),7.44(m,2H),7.00(m,3H),6.82(m,1H),6.40(m,1H),6.28(m,1H),5.77(m,1H),3.66(m,4H),3.16(m,4H),2.44(s,3H).
实施例13:N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)硫)苯基)丙烯酰胺的制备
与实施例5的制备方法相同,除了用间氨基苯硫酚替代间苯二胺,得到标题化合物。
MS:m/z=471.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.69(s,1H),10.54(s,1H),8.31(s,1H),7.91(m,1H),7.73(m,3H),7.48(m,2H),7.06(m,3H),6.88(m,1H),6.45(m,1H),6.29(m,1H),5.83(m,1H),3.76(m,4H),3.10(m,4H),2.79(s,3H).
实施例14:N-(3-(甲基(6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺的制备
与实施例5的制备方法相同,除了用N-甲基间苯二胺替代间苯二胺,得到标题化合物。
MS:m/z=468.5[M+H]+。
1H NMR(300MHz,DSMO):δ12.58(s,1H),10.31(s,1H),8.23(s,1H),7.89(m,1H),7.73(m,2H),7.42(m,2H),7.25(m,1H),7.14(m,2H),6.85(m,1H),6.45(m,1H),6.39(m,1H),5.90(m,1H),3.81(m,4H),3.10(m,2H),3.05(m,2H),2.74(s,3H),2.53(s,3H).
实施例15:N-甲基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
步骤1:N-甲基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丙烯酰胺的合成(中间体15A)
将N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺0.71g(1.22mmol)、DMF 10mL加到50mL单口瓶中,冰浴下搅拌,加入NaH 0.04g(1.59mmol),冰浴下搅拌30min,然后将碘甲烷0.17g(1.22mmol)加到5mL DMF中,缓慢滴加到反应瓶中,滴加完后反应4小时。反应完毕后,加入30mL水、30mL乙酸乙酯萃取,有机相分别用饱和氯化钠水溶液30mL、水30mL洗涤一次,无水硫酸钠干燥,减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:石油醚∶乙酸乙酯=2∶1)纯化,得到260mg浅黄色固体状的标题产物,收率:35.8%,纯度:95.0%。
步骤2:N-甲基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的合成(化合物15)
将N-甲基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丙烯酰胺260mg(0.43mmol)加入至25mL反应瓶中,向其中加入二氯甲烷3mL、三氟乙酸3mL,并室温搅拌过夜。然后将反应液减压浓缩至干,并加入甲醇3mL和氨水1mL,室温搅拌1小时。反应完毕后,抽滤,滤饼用水洗涤一次,干燥,得到87mg浅黄色固体状的标题产物,收率:42.7%,纯度:95.0%。
MS:m/z=469.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.57(s,1H),8.26(s,1H),7.82(m,2H),7.73(m,1H),7.58(m,1H),7.38(m,1H),6.99(m,3H),6.79(m,1H),6.40(m,1H),6.27(m,1H),5.75(m,1H),3.35(s,3H),3.26(m,4H),2.45(m,4H),2.32(s,3H).
实施例16:N-甲基-N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例16的制备方法相同,除了使用(4-吗啉基苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=456.2[M+H]+。
1H NMR(300MHz,DMSO):δ12.53(s,1H),8.30(m,1H),7.62(m,2H),7.54(m,1H),7.28(m,3H),7.04(m,2H),6.80(m,1H),6.18(m,2H),5.78(m,1H),3.76(m,4H),3.33(m,3H),3.20(m,4H).
实施例17:N-环丙基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例16的制备方法相同,除了用环丙基溴替代碘甲烷,得到标题化合物。
MS:m/z=495.6[M+H]+。
1H NMR(300MHz,DMSO):δ12.39(s,1H),8.35(m,1H),7.73(m,3H),7.50(m,1H),7.31(m,1H),7.08(m,3H),6.79(m,1H),6.31(m,2H),5.73(m,1H),3.83(m,1H),3.77(m,4H),2.90(m,4H),2.38(m,3H),1.23(m,2H),0.99(m,2H).
实施例18:N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用3-氨基-4-氟苯酚替代间氨基苯酚,得到标题化合物。
MS:m/z=473.1[M+H]+。
1H NMR(300MHz,DMSO):δ12.53(s,1H),10.10(s,1H),8.26(m,1H),8.02(m,1H),7.81(m,2H),7.32(m,1H),7.05(m,3H),6.85(m,1H),6.63(m,1H),6.28(m,1H),5.78(m,1H),3.24(m,4H),2.48(m,4H),2.23(m,3H).
实施例19:N-(2-氟-5-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了在步骤1中使用3-氨基-4-氟苯酚替代间氨基苯酚,在步骤2中使用(4-吗啉基苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=460.2[M+H]+。
1H NMR(300MHz,DMSO):δ12.55(s,1H),10.11(s,1H),8.27(m,1H),8.02(m,1H),7.84(m,2H),7.37(m,1H),7.09(m,3H),6.88(m,1H),6.66(m,1H),6.26(m,1H),5.79(m,1H),3.76(m,4H),3.22(m,4H).
实施例20:N-(4-((6-(4-吗啉苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)吡啶-2-基)丙烯酰胺的制备
与实施例12的制备方法相同,除了在步骤1中使用2-氨基吡啶-4-醇替代间氨基苯酚,在步骤2中使用(4-吗啉基苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=443.2[M+H]+。
1H NMR(300MHz,DMSO):δ12.60(s,1H),10.20(s,1H),8.31(m,1H),8.12(m,1H),7.99(m,1H),7.80(m,2H),7.33(m,1H),7.06(m,2H),6.85(m,1H),6.66(m,1H),6.27(m,1H),5.76(m,1H),3.76(m,4H),3.20(m,4H).
实施例21:N-(2-甲基-5-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了在步骤1中使用3-氨基-4-甲基苯酚替代间氨基苯酚,在步骤2中使用(4-吗啉基苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=456.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.57(s,1H),10.17(s,1H),8.31(m,1H),7.70(m,2H),7.55(m,1H),7.28(m,2H),7.06(m,3H),6.81(m,1H),6.21(m,2H),5.78(m,1H),3.75(m,4H),3.19(m,4H),2.29(s,3H).
实施例22:N-(2-甲氧基-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用3-氨基-4-甲氧基苯酚替代间氨基苯酚,得到标题化合物。
MS:m/z=485.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.51(s,1H),10.19(s,1H),8.27(m,1H),7.63(m,2H),7.58(m,1H),7.21(m,2H),7.03(m,2H),6.75(m,1H),6.25(m,2H),5.69(m,1H),3.86(s,3H),3.69(m,4H),2.85(m,4H),2.33(s,3H).
实施例23:N-(2-氰基-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用3-氨基-4-氰基苯酚替代间氨基苯酚,得到标题化合物。
MS:m/z=480.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.63(s,1H),10.15(s,1H),8.30(m,1H),7.61(m,2H),7.51(m,1H),7.23(m,2H),6.99(m,2H),6.81(m,1H),6.29(m,2H),5.70(m,1H),3.72(m,4H),2.88(m,4H),2.33(s,3H).
实施例24:N-(3-((6-(6-(4-甲基哌嗪-1-基)吡啶-3-基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(6-(4-甲基哌嗪-1-基)吡啶-3-基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=456.6[M+H]+。
1H NMR(300MHz,DMSO):δ12.49(s,1H),10.53(s,1H),8.73(m,1H),8.35(m,1H),7.73(m,2H),7.50(m,1H),7.31(m,1H),7.08(m,1H),6.83(m,2H),6.32(m,2H),5.67(m,1H),3.66(m,4H),2.84(m,4H),2.31(s,3H).
实施例25:N-(3-((6-(3-氟-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(3-氟-4-(4-甲基哌嗪-1-基)苯基)硼酸频哪醇酯(参考文献WO 2012167733制备)替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=473.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.48(s,1H),10.41(s,1H),8.27(s,1H),7.79(m,1H),7.59(m,2H),7.39(m,2H),6.97(m,2H),6.80(m,1H),6.40(m,1H),6.22(m,1H),5.72(m,1H),3.39(m,4H),2.94(m,4H),2.27(s,3H).
实施例26:N-(3-((6-(3-甲氧基-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(3-甲氧基-4-(4-甲基哌嗪-1-基)苯基)硼酸频哪醇酯(参考文献WO 2013053051制备)替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=485.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.39(s,1H),10.17(s,1H),8.29(s,1H),7.69(m,3H),7.40(m,2H),7.09(m,2H),6.83(m,1H),6.33(m,1H),6.25(m,1H),5.73(m,1H),3.95(s,3H),3.56(m,4H),2.71(m,4H),2.38(s,3H),2.21(s,3H).
实施例27:N-(3-((6-(3-甲基-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(3-甲基-4-(4-甲基哌嗪-1-基)苯基)硼酸频哪醇酯(参考文献WO 2012048411制备)替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=469.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.50(s,1H),10.31(s,1H),8.24(s,1H),7.79(m,2H),7.65(m,1H),7.37-7.47(m,2H),6.95-7.01(m,2H),6.80(m,1H),6.40(m,1H),6.22(m,1H),5.73(m,1H),3.56(m,4H),2.99(m,4H),2.38(s,3H),2.21(s,3H).
实施例28:N-(3-((6-(3-(二氟甲氧基)-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(3-(二氟甲氧基)-4-(4-甲基哌嗪-1-基)苯基)硼酸频哪醇酯替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=520.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.39(s,1H),10.33(s,1H),8.27(s,1H),7.80(m,1H),7.63(m,2H),7.40(m,3H),6.98(m,2H),6.80(m,1H),6.38(m,1H),6.26(m,1H),5.69(m,1H),3.56(m,4H),2.96(m,4H),2.28(s,3H).
实施例29:N-(3-((6-(4-(二甲氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(4-(二甲氨基)苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=400.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.55(s,1H),10.19(s,1H),8.31(m,1H),7.83(m,2H),7.63(m,1H),7.40(m,2H),6.99(m,3H),6.79(m,1H),6.31(m,2H),5.76(m,1H),3.11(s,6H).
实施例30:N-(3-((6-(4-((二甲氨基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(4-((二甲氨基)甲基)苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=414.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.59(s,1H),10.11(s,1H),8.29(m,1H),7.79(m,2H),7.60(m,1H),7.41(m,2H),7.00(m,3H),6.80(m,1H),6.26(m,2H),5.76(m,1H),3.57(m,2H),2.30(s,6H).
实施例31:N-(3-((6-(4-(2-甲氧基乙氧基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(4-(2-甲氧基乙氧基)苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=431.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.60(s,1H),10.17(s,1H),8.23(m,1H),7.73(m,2H),7.58(m,1H),7.39(m,2H),7.03(m,3H),6.75(m,1H),6.29(m,2H),5.76(m,1H),4.28(m,2H),3.66(m,2H),3.42(s,3H).
实施例32:N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺的制备
与实施例6的制备方法相同,除了用(4-吗啉基苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=441.2[M+H]+。
1H NMR(300MHz,DMSO):δ12.14(s,1H),10.21(s,1H),9.37(m,1H),8.27(m,2H),7.70(m,3H),7.30(m,2H),7.06(m,3H),6.50(m,1H),6.30(m,1H),6.24(m,1H),5.75(m,1H),3.76(m,4H),3.16(m,4H).
实施例33:N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(4-吗啉基苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=442.1[M+H]+。
1H NMR(300MHz,DMSO):δ12.84(s,1H),10.68(s,1H),8.35(m,1H),7.99(m,3H),7.78(m,1H),7.60(m,1H),7.45(m,2H),7.02(m,1H),6.57(m,2H),6.29(m,1H),6.24(m,1H),3.91(m,4H),3.42(m,4H).
实施例34:N-(3-((6-(4-(哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用4-(4-Boc-1-哌嗪基)苯硼酸频哪醇酯替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=441.2[M+H]+。
1H NMR(600MHz,DMSO):δ12.55(s,1H),10.29(s,1H),8.78(s,2H),8.26(m,1H),7.85(m,2H),7.68(m,1H),7.37(m,2H),6.71-7.17(m,6H),6.21-6.38(m,2H),5.73(m,1H),3.43(m,4H),3.23(m,4H).
实施例35:N-(3-((6-(4-(1,1-二氧代硫代吗啉基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
步骤1:(4-(1,1-二氧代硫代吗啉基)苯基)硼酸频哪醇酯的合成(中间体35A)
将4-(4-溴苯基)硫代吗啉-1,1-二氧化物2.0g(6.8mmol)加入至100mL反应瓶中,向其中依次加入乙酸钾1.36g(14.0mmol)、二氧六环40mL、Pd(dppf)Cl20.48g(0.6mmol)、联硼酸频那醇酯1.2g(4.8mmol)。在氩气保护下,将混合物加热至80℃并搅拌反应16小时。将反应液冷却至室温,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯∶石油醚=1∶3)纯化,得到1.1g浅黄色固体的标题产物,收率:48.2%。
步骤2:4-(4-(4-氯-7H-吡咯并[2,3-d]嘧啶-6-基)苯基)硫代吗啉-1,1-二氧化物的合成(中间体35B)
将(4-(1,1-二氧代硫代吗啉基)苯基)硼酸频哪醇酯1.1g(3.3mmol)加入至100mL反应瓶中,向其中依次加入6-溴-4-氯-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶440mg(1.90mmol)、碳酸钾0.53g(3.8mmol)、二氧六环40mL、Pd(dppf)Cl2139mg(0.18mmol)、水4mL。在氩气保护下,将混合物加热至80℃并搅拌反应16小时。将反应液冷却至室温,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯∶石油醚=1∶3)纯化,得到100mg浅黄色固体的标题产物,收率:14.5%。
步骤3:N-(3-((6-(4-(1,1-二氧代硫代吗啉基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的合成(化合物35)
将4-(4-(4-氯-7H-吡咯并[2,3-d]嘧啶-6-基)苯基)硫代吗啉-1,1-二氧化物100mg(0.28mmol)、N-(3-羟基苯基)丙烯酰胺50mg(0.31mmol)、碳酸钾75mg(0.54mmol)、DMF10mL依次加入单口瓶中,将混合物加热至130℃并搅拌4小时。然后将反应液冷却至室温,并减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=40∶1)纯化,得到5mg黄色固体状的标题产物,收率:3.7%。
MS:m/z=490.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.67(s,1H),10.38(s,1H),8.29(m,1H),7.88(m,2H),7.65(m,1H),7.45(m,4H),7.02(m,2H),6.27(m,2H),5.79(m,1H),3.21(m,4H),2.98(m,4H).
实施例36:N-(3-((6-(4-(4-(2,2,2-三氟乙基)哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
步骤1:1-(4-溴苯基)哌嗪盐酸盐的合成(中间体36A)
4-(4-溴苯基)哌嗪-1-甲酸叔丁酯(2.6g,7.65mmol)溶于4M盐酸/二氧六环(50mL)中,在室温下搅拌24小时。将反应液减压浓缩至干,得到2.50g白色固体的标题产物,收率:100%。
步骤2:1-(4-(4-溴苯基)哌嗪-1-基)-2,2,2-三氟乙-1-酮的合成(中间体36B)
将1-(4-溴苯基)哌嗪盐酸盐(900mg,3.24mmol)溶于二氯甲烷(50mL)中,加入三乙胺(1.5g,15mmol),在室温下缓慢滴加三氟乙酸酐(900mg,4.29mmol),滴加完毕后,室温下搅拌16小时。向反应液中加入水(50mL)萃取,收集有机相,用饱和食盐水(50mL)洗涤,五水硫酸钠干燥,过滤,减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1-二氯甲烷∶甲醇=20∶1)纯化,得到1000mg黄色固体状的标题产物,收率:92.6%。
步骤3:1-(4-溴苯基)-4-(2,2,2-三氟乙基)哌嗪的合成(中间体36C)
将1-(4-(4-溴苯基)哌嗪-1-基)-2,2,2-三氟乙-1-酮(1.00g,3.00mmol)溶于五水四氢呋喃(30mL)中,加入硼烷二甲硫醚(10M,1.5mL),反应液加热回流6小时后,冷却至室温,逐滴加入甲醇淬灭,减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1-二氯甲烷∶甲醇=20∶1)纯化,得到900mg黄色固体状的标题产物,收率:93.2%。
随后步骤与实施例35的制备方法相同,除了用1-(4-溴苯基)-4-(2,2,2-三氟乙基)哌嗪替代4-(4-溴苯基)硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=523.2[M+H]+。
1H NMR(600MHz,DMSO):δ12.50(s,1H),10.26(s,1H),8.24(s,1H),7.79(m,2H),7.65(m,1H),7.37-7.47(m,2H),6.95-7.01(m,3H),6.80(m,1H),6.40(m,1H),6.22(m,1H),5.73(m,1H),3.23(m,6H),2.74(m,4H).
实施例37:N-(3-((6-(4-(6-甲基-2,6-二氮杂螺[3.3]庚烷-2-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
步骤1:2-(4-碘苯基)-6-甲基-2,6-二氮杂螺[3.3]庚烷的制备(中间体37A)
在氮气保护下,向20mL DMF中依次加入对二碘苯(3.30g,10mmol)、6-甲基-2,6-二氮杂螺[3.3]庚烷草酸盐(2.02g,10mmol)、磷酸钾(4.24g,20mmol)、碘化亚铜(0.19g,1mmol)和1,1′-联-2-萘酚(0.28g,1mmol),混合液在室温下搅拌反应48个小时。向反应液中加入40mL水,用乙酸乙酯(30mL×3)萃取,有机相合并后用无水硫酸钠干燥,过滤,浓缩。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=50∶1-二氯甲烷∶甲醇=20∶1)纯化,得到2.13g黄色油状的标题产物,收率:67.8%。
随后步骤与实施例35的制备方法相同,除了用2-(4-碘苯基)-6-甲基-2,6-二氮杂螺[3.3]庚烷替代4-(4-溴苯基)硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=467.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.62(s,1H),10.30(s,1H),8.22(s,1H),7.80(m,2H),7.65(m,1H),7.40(m,2H),6.98(m,3H),6.35-6.75(m,2H),6.23(m,1H),5.71(m,1H),3.58(m,4H),3.20(m,4H),2.30(s,3H).
实施例38:N-(3-((6-(4-(2-硫代-6-氮杂螺[3.3]庚烷-6-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例37的制备方法相同,除了用2-硫-6-氮杂螺[3.3]庚烷草酸盐替代6-甲基-2,6-二氮杂螺[3.3]庚烷草酸盐,得到标题化合物。
MS:m/z=470.2[M+H]+。
1H NMR(300MHz,DMSO):δ12.59(s,1H),10.33(s,1H),8.22(s,1H),7.80(m,2H),7.64(m,1H),7.38(m,2H),7.05(m,3H),6.40(m,2H),6.23(m,1H),5.68(m,1H),3.61(m,4H),3.10(m,4H).
实施例39:N-(3-((6-(4-(4-乙酰基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用4-(4-乙酰基哌嗪)苯硼酸频那醇酯替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=483.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.56(s,1H),10.32(s,1H),8.28(m,1H),7.83(m,2H),7.70(m,1H),7.41(m,1H),7.35(m,1H),7.00(m,3H),6.85(m,1H),6.43(m,1H),6.25(m,1H),5.77(m,1H),3.59(m,4H),3.22(m,4H),2.05(s,3H).
实施例40:N-(3-((6-(4-(2,4-二甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(4-(2,4-二甲基哌嗪-1-基)苯基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=469.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.59(s,1H),10.38(s,1H),8.26(s,1H),7.82(m,2H),7.66(m,1H),7.37(m,2H),6.99(m,3H),6.83(m,1H),6.43(m,1H),6.20(m,1H),5.69(m,1H),3.44-2.78(m,6H),2.32(m,1H),2.29(m,3H),1.21(m,3H).
实施例41:1-(4-(4-(3-丙烯酰胺基苯氧基)-7H-吡咯并[2,3-d]嘧啶-6-基)苯基)-4-甲基哌嗪-2-羧酸的制备
与实施例37的制备方法相同,除了用4-甲基哌嗪-2-羧酸替代6-甲基-2,6-二氮杂螺[3.3]庚烷草酸盐,得到标题化合物。
MS:m/z=499.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.50(s,1H),10.31(s,1H),8.28(s,1H),7.82(m,2H),7.65(m,1H),7.31(m,2H),7.01(m,3H),6.85(m,1H),6.44(m,1H),6.20(m,1H),5.65(m,1H),4.32(m,1H),3.50(m,2H),3.18(m,4H),2.33(s,3H).
实施例42:N-(3-((6-(4-(4,4-二氟哌啶-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例37的制备方法相同,除了用4,4-二氟哌啶替代6-甲基-2,6-二氮杂螺[3.3]庚烷草酸盐,得到标题化合物。
MS:m/z=476.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.50(s,1H),10.38(s,1H),8.28(s,1H),7.88(m,2H),7.70(m,1H),7.29(m,2H),7.05(m,3H),6.84(m,1H),6.38(m,1H),6.25(m,1H),5.68(m,1H),3.47(m,4H),2.03(m,4H).
实施例43:N-(3-((6-(4-(5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例37的制备方法相同,除了用2-甲基八氢吡咯并[3,4-c]吡咯替代6-甲基-2,6-二氮杂螺[3.3]庚烷草酸盐,得到标题化合物。
MS:m/z=481.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.53(s,1H),10.31(s,1H),8.26(s,1H),7.83(m,2H),7.67(m,1H),7.31(m,2H),6.95(m,3H),6.83(m,1H),6.27(m,1H),6.22(m,1H),5.68(m,1H),2.93-3.23(m,6H),2.17-2.43(m,4H),2.07(m,3H).
实施例44:N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
步骤1:(4-(1,1-二氧代硫代吗啉基)甲基)苯基)硼酸频哪醇酯的合成(中间体44A)
将4-溴甲基苯硼酸频哪醇酯5.0g(1.68mmol)、1,1-二氧化物硫代吗啉2.74g(2.02mmol)、碳酸钾2.79g(2.02mmol)加入至反应瓶中,加入DMF 25mL,80℃搅拌反应4小时。冷却至室温,将反应液倒入125mL冰水中,搅拌30min,抽滤得标题产物,白色固体4.72g,收率为79.7%。
步骤2:4-(4-(4-氯-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-6-基)苄基)硫代吗啉-1,1-二氧化物的合成(中间体44B)
6-溴-4-氯-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶1.87g(5.16mmol)加入至100mL反应瓶中,向其中依次加入(4-(1,1-二氧代硫代吗啉基)甲基)苯基)硼酸频哪醇酯1.64g(4.32mmol)、二氧六环20mL、碳酸钠1.33g(12.55mmol)、水4mL、Pd(dppf)Cl20.22g(0.30mmol)。在氩气保护下,将混合物加热至80℃并搅拌反应过夜。反应完毕后,将反应液冷却至室温,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯∶石油醚-乙酸乙酯)纯化,得到1.05g浅粉色固体标题产物,收率:40.2%。
步骤3:N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的合成(中间体44C)
将4-(4-(4-氯-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-6-基)苄基)硫代吗啉-1,1-二氧化物0.46g(0.9mmol)、N-(3-羟基苯基)丙烯酰胺0.32g(2.0mmol)、碳酸钾0.40g(2.9mmol)、DMF 10mL依次加入单口瓶中,将混合物加热至100℃并搅拌4小时。然后将反应液冷却至室温,并减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=40∶1)纯化,得到0.46g黄色固体状的标题产物,收率:80.1%。
步骤4:N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的合成(化合物44)
将N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7-((2-(三甲基硅基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺0.46g(0.7mmol)加入至50mL反应瓶中,向其中加入二氯甲烷5mL、三氟乙酸5mL,并室温搅拌过夜。然后将反应液减压浓缩至干,并加入甲醇20mL和氨水3mL,室温搅拌2小时。反应完毕后,向反应液中加入10mL饱和食盐水,20mL二氯甲烷萃取。有机相浓缩至干,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=10∶1)纯化,得到110mg浅黄色固体状的标题产物,收率:30.1%,纯度:95.3%。
MS:m/z=504.9[M+H]+。
1H NMR(300MHz,DMSO):δ12.73(s,1H),10.32(s,1H),8.33(m,1H),7.94(m,2H),7.71(m,1H),7.44(m,4H),7.02(m,2H),6.29(m,1H),6.23(m,1H),5.79(m,1H),3.72(m,2H),3.14(m,4H),2.90(m,4H).
实施例45:N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺的制备
与实施例5的制备方法相同,除了用(4-(1,1-二氧代硫代吗啉基)甲基)苯基)硼酸频哪醇酯(中间体44A)替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=503.9[M+H]+。
1H NMR(300MHz,DMSO):δ12.27(s,1H),10.17(s,1H),9.45(s,1H),8.29(m,2H),7.81(m,2H),7.67(m,1H),7.44(m,2H),7.31(m,3H),6.50(m,1H),6.28(m,1H),5.76(m,1H),3.71(m,2H),3.13(m,4H),2.91(m,4H).
实施例46:N-(3-((6-(4-(吗啉基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用吗啉替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=455.0[M+H]+。
1H NMR(300MHz,DMSO):δ12.79(s,1H),10.77(s,1H),8.32(m,1H),7.97(m,2H),7.76(m,1H),7.60(m,2H),7.40(m,2H),7.00(m,2H),6.57(m,1H),6.25(m,1H),5.75(m,1H),3.35(s,2H),2.45(m,4H),1.96(m,4H).
实施例47:N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用4,4-二氟哌啶替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=490.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.72(s,1H),10.31(s,1H),8.33(m,1H),7.93(m,2H),7.71(m,1H),7.49(m,1H),7.42(m,3H),7.04(m,2H),6.43(m,1H),6.29(m,1H),5.78(m,1H),3.59(s,2H),2.49(m,4H),1.97(m,4H).
实施例48:N-(3-((6-(4-(哌啶-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用哌啶替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=454.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.52(s,1H),10.33(s,1H),8.33(m,1H),7.94(m,2H),7.72(m,1H),7.50(m,1H),7.42(m,3H),7.05(m,1H),7.00(m,1H),6.43(m,1H),6.26(m,1H),5.76(m,1H),3.60(s,2H),2.50(m,4H),1.55(m,4H),1.43(m,2H).
实施例49:N-(3-((6-(4-(吡咯烷-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用吡咯烷替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=440.1[M+H]+。
1H NMR(300MHz,DMSO):δ12.65(s,1H),10.55(s,1H),8.30(s,1H),7.90(m,2H),7.69(m,1H),7.50(m,2H),7.11(m,3H),6.85(m,1H),6.50(m,1H),6.26(m,1H),5.77(m,1H),3.38(m,2H),3.05(m,2H),2.49(m,2H),1.74(m,4H).
实施例50:N-(3-((6-(4-((6-甲基-2,6-二氮杂螺[3.3]庚烷-2-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用2-甲基-2,6-二氮杂螺[3.3]庚烷草酸盐替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=481.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.70(s,1H),10.52(s,1H),8.28(s,1H),7.88(m,2H),7.70(m,1H),7.48(m,2H),7.00-7.33(m,3H),6.85(m,1H),6.49(m,1H),6.30(m,1H),5.76(m,1H),3.46(m,2H),3.40-3.25(m,8H),2.25(s,3H).
实施例51:N-(3-((6-(4-((5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用2-甲基八氢吡咯并[3,4-c]吡咯替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=495.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.68(s,1H),10.37(s,1H),8.31(s,1H),7.79(m,2H),7.71(m,1H),7.58(m,2H),7.42(m,2H),6.91(m,2H),6.51(m,1H),6.27(m,1H),5.78(m,1H),3.39(m,2H),3.19(m,2H),2.56(m,4H),2.19(m,4H),2.08(s,3H).
实施例52:N-(3-((6-(4-((3-甲基-3,8-二氮杂双环[3.2.1]辛烷-8基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用3-甲基-3,8-二氮杂双环[3.2.1]辛烷二盐酸盐替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=495.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.71(s,1H),10.31(s,1H),8.27(s,1H),7.80(m,2H),7.69(m,1H),7.60(m,2H),7.40(m,2H),6.99(m,2H),6.53(m,1H),6.31(m,1H),5.76(m,1H),3.66(m,2H),2.89(m,2H),2.52(m,2H),2.27(m,2H),2.20(m,5H),1.45-1.66(m,4H).
实施例53:N-(3-((6-(4-((1-甲基哌啶-4-基)氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
步骤1:N-(4-溴苯基)-1-甲基哌啶-4-胺的合成(中间体54A)
将4-溴苯胺(4.30g,25mmol)和1-甲基哌啶-4-酮(2.83g,25mmol)溶于100mL无水四氢呋喃中,室温下搅拌2小时,随后加入三乙酰氧基硼氢化钠(10.6g,50mmol),反应液回流20个小时。将反应液冷却至室温,过滤,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=30∶1~二氯甲烷∶甲醇=10∶1)纯化,得到4.28g白色固体的标题产物,收率:64.0%。
步骤2:(4-((1-甲基哌啶-4-基)氨基)苯基)硼酸频哪醇酯的合成(中间体54B)
将N-(4-溴苯基)-1-甲基哌啶-4-胺(3.0g,11.2mmol)、联硼酸频那醇酯(4.24g,16.7mmol)、醋酸钾(2.19g,22.3mmol)和Pd(dppf)Cl2(0.81g,1.1mmol)依次加入到80mL二氧六环中,氮气保护下升温至100℃,搅拌20小时。将反应液冷却至室温,过滤,滤饼用少量乙酸乙酯洗涤。合并滤液,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:二氯甲烷∶甲醇=30∶1~二氯甲烷∶甲醇=10∶1)纯化,得到1.66g棕色油状物的标题产物,收率:47.0%。
其余步骤与实施例12的步骤2、3和4的过程相同,除了用(4-((1-甲基哌啶-4-基)氨基)苯基)硼酸频哪醇酯(中间体54B)替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=469.4[M+H]+。
1H NMR(600MHz,DMSO):δ12.36(s,1H),10.26(s,1H),8.21(m,1H),7.81(m,3H),7.45(m,1H),7.36(m,1H),6.97(m,1H),6.64(m,3H),6.39(m,1H),6.21(m,1H),5.75(m,2H),3.23(m,1H),2.78(m,2H),2.17(s,3H),2.06(m,2H),1.87(m,2H),1.40(m,2H).
实施例54:N-(3-((6-(4-(吗啉-4-甲酰基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例35的制备方法相同,除了用(4-溴苯基)(吗啉基)酮(参考文献Tetrahedron,2010,66,1472制备)替代4-(4-溴苯基)硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=470.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.50(s,1H),10.40(s,1H),8.31(s,1H),7.80(m,2H),7.60(m,1H),7.40(m,2H),7.00(m,3H),6.81(m,1H),6.36(m,1H),6.23(m,1H),5.69(m,1H),3.75-3.50(m,8H).
实施例55:N-(3-((6-(4-((1-甲基哌啶-4-基)氧)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例35的制备方法相同,除了用4-(4-溴苯氧基)-1-甲基哌啶(参考文献WO2011123946制备)替代4-(4-溴苯基)硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=470.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.66(s,1H),10.29(s,1H),8.29(m,1H),7.89(m,2H),7.71(m,1H),7.33(m,4H),6.98(m,2H),6.39(m,1H),6.22(m,1H),5.69(m,1H),4.10(m,1H),2.75(m,2H),2.40(m,2H),2.11(m,2H),1.95(m,2H).
实施例56:N-(3-((6-(4-(甲基(1-甲基哌啶-4-基)氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例54的制备方法相同,除了用4-溴-N-甲基苯胺替代4-溴苯胺,得到标题化合物。
MS:m/z=483.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.38(s,1H),10.20(s,1H),8.29(m,1H),7.85(m,2H),7.69(m,1H),7.40(m,2H),7.19(m,3H),6.81(m,1H),6.49(m,1H),6.25(m,1H),5.73(m,1H),3.61(m,1H),2.85(s,3H),2.77-2.38(m,4H),2.28(s,3H),2.03-1.81(m,4H).
实施例57:N-(3-((6-(4-((4-甲基哌嗪-1-基)磺酰基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例35的制备方法相同,除了用1-((4-溴苯基)磺酰基)-4-甲基哌嗪替代4-(4-溴苯基)硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=519.2[M+H]+。
1H NMR(300MHz,DMSO):δ12.51(s,1H),10.38(s,1H),8.29(s,1H),7.87(m,2H),7.67(m,1H),7.48(m,2H),7.09(m,3H),6.88(m,1H),6.53(m,1H),6.28(m,1H),5.71(m,1H),3.28(m,4H),2.51(m,4H).
实施例58:N-(3-((6-(4-(((1-甲基哌啶-4-基)氧)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用1-甲基-哌啶-4-醇替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=484.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.69(s,1H),10.50(s,1H),8.33(s,1H),7.81(m,2H),7.60(m,1H),7.51(m,2H),6.99(m,3H),6.82(m,1H),6.55(m,1H),6.27(m,1H),5.66(m,1H),4.80(s,2H),3.89(m,1H),2.58(m,4H),2.26(s,3H),1.88(m,4H).
实施例59:N-(3-((6-(4-(((1-甲基哌啶-4-基)氨基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用1-甲基哌啶-4-胺替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=483.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.71(s,1H),10.39(s,1H),8.28(s,1H),7.79(m,2H),7.57(m,1H),7.51(m,2H),6.99(m,3H),6.83(m,1H),6.57(m,1H),6.29(m,1H),5.73(m,1H),3.98(s,2H),2.78(m,1H),2.55(m,4H),2.28(s,3H),1.88(m,2H),1.49(m,2H).
实施例60:N-(3-((6-(4-((甲基(1-甲基哌啶-4-基)氨基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用N,1-二甲基哌啶-4-胺替代硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=497.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.70(s,1H),10.69(s,1H),8.35(m,1H),7.90(m,2H),7.73(m,1H),7.55(m,2H),7.39(m,2H),7.00(m,2H),6.57(m,1H),6.25(m,1H),5.75(m,1H),4.07(m,1H),3.69(m,1H),2.57(m,4H),2.40(m,1H),2.32(s,3H),2.26(s,3H),1.95(m,2H),1.55(m,2H).
实施例61:N-(4-(4-(3-丙烯酰胺基苯氧基)-7H-吡咯并[2,3-d]嘧啶-6-基)苯基)-1-甲基哌啶-4-甲酰胺的制备
与实施例35的制备方法相同,除了用N-(4-溴苯基)-1-甲基哌啶-4-甲酰胺(参考文献WO 2010054279制备)替代4-(4-溴苯基)硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=496.4[M+H]+。
1H NMR(300MHz,DMSO):δ12.55(s,1H),10.41(s,1H),9.38(s,1H),8.33(s,1H),7.87(m,2H),7.69(m,1H),7.48(m,2H),7.19(m,3H),6.85(m,1H),6.53(m,1H),6.27(m,1H),5.67(m,1H),2.75-2.40(m,5H),2.33(m,2H),1.73(m,2H).
实施例62:N-(3-((6-(4-(4-(乙基磺酰基)哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例35的制备方法相同,除了用1-(4-溴苯基)-4-(乙基磺酰基)哌嗪替代4-(4-溴苯基)硫代吗啉-1,1-二氧化物,得到标题化合物。
MS:m/z=533.2[M+H]+。
1H NMR(600MHz,DMSO):δ12.55(s,1H),10.38(s,1H),8.25(m,1H),7.81(m,2H),7.49(m,3H),6.96(m,4H),6.47(m,1H),6.21(m,1H),5.73(m,1H),3.35(m,8H),3.08(m,2H),1.21(m,3H).
实施例63:N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-炔酰胺的制备
步骤1:(4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)苄基)哌啶的合成(中间体63A)
将4-溴甲基苯硼酸频哪醇酯5.0g(1.68mmol)、4,4-二氟哌啶2.44g(2.02mmol)、碳酸钾2.79g(2.02mmol)加入至反应瓶中,加入DMF 25mL,80℃搅拌反应4小时。冷却至室温,将反应液倒入125mL冰水中,搅拌30min,抽滤得标题产物,白色固体5.06g,收率为88.8%。
步骤2:4-氯-6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶的合成(中间体63B)
6-溴-4-氯-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶1.87g(5.16mmol)加入至100mL反应瓶中,向其中依次加入(4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)苄基)哌啶1.46g(4.32mmol)、二氧六环20mL、碳酸钠1.33g(12.55mmol)、水4mL、Pd(dppf)Cl20.22g(0.30mmol)。在氩气保护下,将混合物加热至80℃并搅拌反应过夜。反应完毕后,将反应液冷却至室温,并减压浓缩至干,将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯∶石油醚=1∶5)纯化,得到1.22g浅黄色固体标题产物,收率:47.9%。
步骤3:3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯胺的合成(中间体63C)
将4-氯-6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶1.20g(2.44mmol)加入至50mL反应瓶中,并向其中加入间氨基苯酚0.32g(2.93mmol)、碳酸钾0.67g(4.88mmol)、DMF 15mL,将反应液升温至100℃搅拌过夜。反应完毕后,减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯∶石油醚=2∶1)纯化,得0.40g浅黄色油状物标题产物,收率:29.0%,纯度97.0%。
步骤4:N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3d]嘧啶-4-基)氧基)苯基)丁-2-炔酰胺的合成(中间体63D)
丁-2-炔酰氯的制备:
将2-丁炔酸1.0g(11.9mmol)加入至50mL反应瓶中,并向其中加入THF(20mL),室温搅拌,缓慢滴加草酰氯1.2mL,滴加完后加DMF 3滴,室温搅拌1小时。浓缩至干备用。
将3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯胺0.4g(1.22mmol)加入至50mL反应瓶中,并向其中加入碳酸氢钠0.12g(1.46mmol)、THF 20mL、水4mL,冰浴下搅拌,将上面制备的丁-2-炔酰氯加入到10mL THF中,缓慢滴加到反应瓶中,滴加完后室温搅拌1小时。反应完毕后,加50mL氯化铵饱和水溶液淬灭,加50mL二氯甲烷萃取,有机层加无水硫酸钠干燥,减压浓缩至干。将残余物通过柱层析色谱法(洗脱剂:乙酸乙酯∶石油醚=2∶1)纯化,得170mg浅黄色油状物标题产物,收率:38.0%,纯度96.4%。
步骤5:N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-炔酰胺的合成(化合物63)
将N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7-((2-(三甲基硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-炔酰胺170mg(0.27mmol)加入至50mL反应瓶中,并向其中加入二氯甲烷2mL、三氟乙酸2mL,将反应液室温搅拌过夜,然后减压浓缩至干。向残余物中加入甲醇3mL和氨水1mL,室温搅拌1小时。反应完毕后,抽滤,滤饼用5mL水洗涤,干燥滤饼,得20mg浅黄色固体标题产物,收率:14.8%,纯度95.0%。
MS:m/z=502.2[M+H]+。
1H NMR(300MHz,DMSO):δ12.40(s,1H),9.81(s,1H),8.20(m,1H),7.93(m,2H),7.70(m,1H),7.47(m,1H),7.40(m,3H),7.00(m,2H),3.49(s,2H),2.40(m,4H),2.19(m,3H),1.97(m,4H).
实施例64:N-(3-((6-(4-(哌啶-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-炔酰胺的制备
与实施例63的制备方法相同,除了用哌啶替代4,4-二氟哌啶,得到标题化合物。
MS:m/z=497.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.43(s,1H),9.81(s,1H),8.15(m,1H),7.93(m,2H),7.71(m,1H),7.49(m,1H),7.43(m,3H),7.02(m,2H),3.48(s,2H),2.37(m,4H),2.19(m,3H),1.57(m,4H),1.43(m,2H).
实施例65:N-(3-((6-(5-(4-甲基哌嗪-1-基)吡啶-2-基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(5-(4-甲基哌嗪-1-基)吡啶-2-基)硼酸替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=456.5[M+H]+。
1H NMR(300MHz,DMSO):δ12.48(s,1H),10.23(s,1H),8.76(m,1H),8.40(m,1H),7.75(m,2H),7.45(m,1H),7.29(m,1H),7.08(m,1H),6.86(m,2H),6.30(m,2H),5.67(m,1H),3.58(m,4H),2.86(m,4H),2.29(s,3H).
实施例66:N-(3-((6-(5-((4,4-二氟哌啶-1-基)甲基)吡啶-2-基)-7H-吡咯[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例44的制备方法相同,除了用4,4-二氟哌啶替代硫代吗啉-1,1-二氧化物,用(5-(溴甲基)吡啶-2-基)硼酸频哪醇酯替代4-溴甲基苯硼酸频哪醇酯,得到标题化合物。
MS:m/z=491.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.68(s,1H),10.31(s,1H),8.73(m,1H),8.38(m,1H),7.80(m,2H),7.49(m,1H),7.27(m,1H),7.04(m,1H),6.43(m,1H),6.29(m,1H),5.75(m,1H),3.61(s,2H),2.50(m,4H),1.95(m,4H).
实施例67:N-(3-((6-(2-氟-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺的制备
与实施例12的制备方法相同,除了用(2-氟-4-(4-甲基哌嗪-1-基)苯基)硼酸频哪醇酯替代(4-(4-甲基哌嗪-1-基)苯基)硼酸,得到标题化合物。
MS:m/z=473.3[M+H]+。
1H NMR(300MHz,DMSO):δ12.47(s,1H),10.43(s,1H),8.26(s,1H),7.83(m,1H),7.66(m,2H),7.41(m,2H),6.95(m,2H),6.80(m,1H),6.40(m,1H),6.27(m,1H),5.70(m,1H),3.34(m,4H),2.90(m,4H),2.27(s,3H).
本发明化合物的生物学评价
试验例1:BTK抑制活性的评价
向384反应板(6008280,PerkinElmer)中加入2μL/孔的BTK溶液(购自Promega公司)。用100%DMSO将待测化合物(10mM储液)稀释100倍至100μM,在384稀释板中(3657,corning)以1:3进行等比稀释,待测化合物的梯度浓度为100、33.3、11.1、3.7、1.24、0.41、0.14、0.046、0.015、0.0051、0μM。转移2μL的待测化合物到含有38μL的1X激酶反应缓冲液的384稀释板中,混匀并1000rpm离心。转移1μL的待测化合物到384反应板中,1000rpm离心并25℃孵育15分钟。转移2μL底物混合物(ATP:10mM,4μL;Poly E4Y1:1mg/mL,20μL;激酶反应缓冲液:776μL)到384反应板中,1000rpm离心并25℃孵育60分钟。待测化合物在反应体系中,终浓度梯度为1000、333.3、111.1、37.03、12.35、4.14、1.37、0.46、0.15、0.051、0nM。DMSO终浓度为1%。转移5μL ADP-Glo溶液(购自Promega公司)到384反应板中,1000rpm离心并25℃孵育40分钟。转移10μL Detection溶液到384反应板中,1000rpm离心并25℃孵育40分钟。使用Envision多功能读板机(Perkin Elmer)读取RLU(Relative luminescenceunit)信号,信号强度用于表征BTK激酶的活性程度。通过使用Microsoft Excel进行IC50的计算和分析。测试结果在表1中示出。
在表1中,A是指IC50<100nM;B是指IC50=100nM至500nM;C是指IC50=500nM至1,000nM;D是指IC50>1,000nM。
表1 BTK抑制活性
结论:如上表所示,本发明化合物均显示出了优异的BTK抑制活性。
测试例2:二型胶原诱导的DBA/1J小鼠关节炎模型(CIA)
CIA模型是一个被广泛用于研究治疗人类风湿关节炎药物活性的动物模型。
动物:DBA/1小鼠,性别:雄性,数量:30只,体重:14-16g,周龄范围:6-7周龄,购于北京市维通利华实验动物技术有限公司,SPF级,动物生产许可证号:SCXK(京)2012-0001,发证单位:北京市科学技术委员会。
分组:模型对照组,给药(30mg/Kg)组(实施例33化合物)
取适量Bovine Type II Collage(购于Chondrex.Inc),溶于0.05M乙酸中(4mg胶原/mL),4℃冰箱过夜。与等量完全弗氏佐剂在冰浴环境下充分乳化,每只DBA/1J小鼠以0.1mL(含胶原200μg)乳剂,于尾根部1.5cm处皮下注射。于造模后4周开始进行临床症状观察和关节炎评分,将全部出现症状的动物的评分进行排序后逐层随机分组,分为2组,分别为模型对照组(口服灌胃给予等量的溶媒0.5%CMC)和给药组(口服灌胃给予30mg/kg的实施例33化合物);1次/天给药,持续给予21天;给药后每隔3天测量观察一次关节炎评分和体重变化。
关节炎指数评分:按Wood氏的关节炎评分标准作关节炎指数评分,具体如下。
0分:正常
1分:红肿涉及1个指关节
2分:红肿涉及2个以上指关节或整个足爪轻度红肿
3分:足爪红肿较重
4分:足爪重度红肿,关节僵硬、缺乏弹性。
4只足爪中每只爪的损害都分为0-4计算四肢的总积分。比较不同时间的积分(关节炎指数)。
表2本发明实施例33化合物对CIA模型动物关节炎评分的影响
注明:与模型对照组比较*P<0.05,**P<0.01
结论:本发明化合物显著降低CIA模型动物的关节炎评分,说明本发明化合物对CIA小鼠的关节炎症状有明显的改善作用。
Claims (11)
1.一种通式III所示的化合物或其可药用盐,
其中:
W选自N或CR1;
R1选自氢、卤素、C1-6烷基;
A选自N或CRc;
Rc选自氢或卤素;
X选自-O-、-NR2-、-S-;
R2选自氢或C1-6烷基;
n是0;
R3选自氢或C1-6烷基;
R4和R5各自独立地选自氢和C1-6烷基;
E选自N或CRd;
Rd选自氢、卤素、C1-6烷基、C1-6卤代烷基;
L1和L2各自独立地选自单键、-(CH2)m-、-NR6-;
m是1;
R6选自氢或C1-6烷基;
R7选自5-8元杂环基;其中所述5-8元杂环基任选被一个或多个R8取代;
每个R8各自独立地选自卤素、氧代基、C1-6烷基;其中所述C1-6烷基任选被卤素取代;
R9选自氢、卤素、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基。
2.根据权利要求1所述的通式III所示的化合物或其可药用盐,其为通式IV所示的化合物或其可药用盐,
W选自N或CR1;
R1选自氢、卤素、C1-6烷基;
X选自-O-、-NR2-和-S-;
R2选自氢或C1-6烷基;
A选自N或CRc;
Rc选自氢或卤素;
R3选自氢或C1-6烷基;
R9选自氢、卤素、C1-6烷基、C1-6烷氧基、C1-6卤代烷基、C1-6卤代烷氧基;
L1和L2各自独立地选自单键、-(CH2)m-、-NR6-;
m是1;
R6选自氢或C1-6烷基;
R7选自5-8元杂环基;其中所述5-8元杂环基任选被一个或多个R8取代;
每个R8各自独立地选自卤素、氧代基、C1-6烷基,所述C1-6烷基任选被卤素取代。
4.根据权利要求1至3中任一项所述的通式III所示的化合物或其可药用盐,其中所述化合物选自:
N-(3-((5-氯-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺;
N-(3-((5-氟-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺;
N-(3-((5-甲基-2-(4-(4-甲基哌嗪-1基)苯基)-1H-吡咯并[2,3-b]吡啶-4基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺;
N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)硫)苯基)丙烯酰胺;
N-(3-(甲基(6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-甲基-N-(3-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-甲基-N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(2-氟-5-((6-(4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(2-氟-5-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(4-((6-(4-吗啉苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)吡啶-2-基)丙烯酰胺;
N-(2-甲基-5-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(6-(4-甲基哌嗪-1-基)吡啶-3-基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-氟-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-甲氧基-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-甲基-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(3-(二氟甲氧基)-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-(3-((6-(4-吗啉基苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(1,1-二氧代硫代吗啉基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4-(2,2,2-三氟乙基)哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(6-甲基-2,6-二氮杂螺[3.3]庚烷-2-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(2-硫代-6-氮杂螺[3.3]庚烷-6-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(2,4-二甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(4,4-二氟哌啶-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((1,1-二氧代硫代吗啉基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)苯基)丙烯酰胺;
N-(3-((6-(4-(吗啉基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(哌啶-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(吡咯烷-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((6-甲基-2,6-二氮杂螺[3.3]庚烷-2-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((3-甲基-3,8-二氮杂双环[3.2.1]辛烷-8-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((1-甲基哌啶-4-基)氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-(甲基(1-甲基哌啶-4-基)氨基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(4-((4,4-二氟哌啶-1-基)甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丁-2-炔酰胺;
N-(3-((6-(4-(哌啶-1-基甲基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)苯基)丁-2-炔酰胺;
N-(3-((6-(5-(4-甲基哌嗪-1-基)吡啶-2-基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(5-((4,4-二氟哌啶-1-基)甲基)吡啶-2-基)-7H-吡咯[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺;
N-(3-((6-(2-氟-4-(4-甲基哌嗪-1-基)苯基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧)苯基)丙烯酰胺。
5.一种药物组合物,其含有根据权利要求1至4中任一项所述的通式III所示的化合物或其可药用盐,以及药学上可接受的载体。
6.根据权利要求1至4中任一项所述的通式III所示的化合物或其可药用盐或者根据权利要求5所述的药物组合物在制备BTK激酶抑制剂中的用途。
7.根据权利要求1至4中任一项所述的通式III所示的化合物或其可药用盐或者根据权利要求5所述的药物组合物在制备预防和/或治疗与BTK激酶活性相关的疾病的药物中的用途。
8.根据权利要求7所述的用途,其中所述疾病选自炎症、自身免疫性疾病、或癌症。
9.根据权利要求8所述的用途,其中所述炎症为关节炎、炎症性肠炎或葡萄膜炎;所述自身免疫性疾病为多发性硬化症、狼疮、银屑病或结节病;所述癌症为乳腺癌、宫颈癌、结肠癌、肺癌、胃癌、直肠癌、胰腺癌、皮肤癌、前列腺癌、骨癌、肾癌、膀胱癌、肝癌、输卵管肿瘤、卵巢瘤、腹膜肿瘤、黑色素瘤、神经胶质瘤、乳突肾性瘤、头颈部肿瘤、白血病、淋巴瘤或骨髓瘤。
10.根据权利要求9所述的用途,其中所述关节炎是类风湿性关节炎或银屑病性关节炎。
11.根据权利要求8所述的用途,其中所述癌症为脑癌、口腔癌、卵巢癌、神经胶母细胞瘤、肝细胞癌或非小细胞肺癌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017100687987 | 2017-02-08 | ||
CN201710068798 | 2017-02-08 | ||
PCT/CN2017/118424 WO2018145525A1 (zh) | 2017-02-08 | 2017-12-26 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110072865A CN110072865A (zh) | 2019-07-30 |
CN110072865B true CN110072865B (zh) | 2022-02-11 |
Family
ID=63107868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780076186.0A Active CN110072865B (zh) | 2017-02-08 | 2017-12-26 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11608334B2 (zh) |
EP (1) | EP3556761B1 (zh) |
JP (1) | JP7164203B2 (zh) |
CN (1) | CN110072865B (zh) |
WO (1) | WO2018145525A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
WO2021037188A1 (zh) * | 2019-08-29 | 2021-03-04 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吡呤化合物的制药用途 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN112812117B (zh) * | 2019-11-18 | 2023-12-22 | 中国医药研究开发中心有限公司 | 一种btk抑制剂的新晶型及其制备方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004833A2 (en) * | 2004-06-28 | 2006-01-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
CN103732596A (zh) * | 2011-07-08 | 2014-04-16 | 诺华股份有限公司 | 新的吡咯并嘧啶衍生物 |
CN103748096A (zh) * | 2012-08-06 | 2014-04-23 | 美国艾森生物科学公司 | 作为蛋白激酶抑制剂的新型吡咯并嘧啶化合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054279A1 (en) | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
JP5918693B2 (ja) * | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Egfr阻害剤及び疾患の治療方法 |
SG183875A1 (en) | 2010-04-06 | 2012-10-30 | Univ Health Network | Kinase inhibitors and method of treating cancer with same |
WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
WO2013053051A1 (en) | 2011-10-12 | 2013-04-18 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
AU2013250726B2 (en) * | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
BR112016000195A8 (pt) * | 2013-07-11 | 2019-12-31 | Acea Biosciences Inc | compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias |
EP3444251B1 (en) * | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
WO2016004305A2 (en) * | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
KR101692510B1 (ko) * | 2015-06-16 | 2017-01-03 | 엘지이노텍 주식회사 | 내구성 향상을 위한 무선충전장치 |
KR20180051220A (ko) * | 2016-11-08 | 2018-05-16 | 주식회사 대웅제약 | 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물 |
-
2017
- 2017-12-26 WO PCT/CN2017/118424 patent/WO2018145525A1/zh unknown
- 2017-12-26 JP JP2019542511A patent/JP7164203B2/ja active Active
- 2017-12-26 US US16/481,925 patent/US11608334B2/en active Active
- 2017-12-26 CN CN201780076186.0A patent/CN110072865B/zh active Active
- 2017-12-26 EP EP17896079.5A patent/EP3556761B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004833A2 (en) * | 2004-06-28 | 2006-01-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
CN103732596A (zh) * | 2011-07-08 | 2014-04-16 | 诺华股份有限公司 | 新的吡咯并嘧啶衍生物 |
WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
CN103748096A (zh) * | 2012-08-06 | 2014-04-23 | 美国艾森生物科学公司 | 作为蛋白激酶抑制剂的新型吡咯并嘧啶化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN110072865A (zh) | 2019-07-30 |
US11608334B2 (en) | 2023-03-21 |
EP3556761B1 (en) | 2021-03-03 |
WO2018145525A1 (zh) | 2018-08-16 |
US20200062749A1 (en) | 2020-02-27 |
JP2020509999A (ja) | 2020-04-02 |
EP3556761A4 (en) | 2019-12-25 |
EP3556761A1 (en) | 2019-10-23 |
JP7164203B2 (ja) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110072865B (zh) | 吡咯并芳杂环类化合物及其制备方法和医药用途 | |
CN107759587B (zh) | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 | |
CN109476641B (zh) | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 | |
JP6847844B2 (ja) | 治療用ピリダジン化合物およびその使用 | |
WO2020239077A1 (zh) | 含氮杂环类衍生物调节剂、其制备方法和应用 | |
CN110627796B (zh) | 含氮杂环类衍生物及其在医药上的应用 | |
KR20180081587A (ko) | 벤조푸란 유도체, 이의 제조 방법 및 의학에서의 이의 용도 | |
CN105980386A (zh) | 吡唑并化合物及其用途 | |
JP7384535B2 (ja) | キナゾリン化合物並びにその調製方法、使用及び医薬組成物 | |
EP3845527A1 (en) | Multi-substituted pyridone derivatives and medical use thereof | |
CN114423760A (zh) | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
CN111320624B (zh) | 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途 | |
CN111320633A (zh) | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 | |
CN108779100B (zh) | 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用 | |
CN107880038B (zh) | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 | |
CN114394965B (zh) | 三唑并吡啶类化合物及其制备方法与用途 | |
CN109206435B (zh) | 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途 | |
TW201835079A (zh) | 6-吡唑-[1,2,4]三唑並[4,3-α]吡啶-3-醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
AU2021282039A1 (en) | Arylformamide compound and preparation method and medical use thereof | |
CN117486890A (zh) | 三环类化合物及其用途 | |
CN116262759B (zh) | 嘧啶三环类化合物及其制备方法和医药用途 | |
WO2021143821A1 (zh) | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 | |
CN117677614A (zh) | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 | |
TW202317572A (zh) | 雜環大環化合物及其醫藥用途 | |
CN114907406A (zh) | 嘧啶衍生物、其制备方法及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40005575 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |